Protocol Number: TROV -052 
Official Title: A Phase 1b/2 Study of Onvansertib (PCM-075) in
Combination with Either Low-dose Cytarabine or Decitabine
in Subjects with Acute Myeloid Leukemia (AML)
N
CT Number: [STUDY_ID_REMOVED]  
D
ocument Date:  07 Aug  2019 
TROV -052 
Clinic
al Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019 
Page 1 of 83 
CONFIDENTIAL  1 CLINICAL STUDY PROTO COL  
Protocol Title:  A Phase 1b/2 Study of Onvansertib ( PCM -075) in 
Combination with E ither Low -dose Cytarabine or Decitabine 
in Subjects with Acute Myeloid Leukemia (AML)  
Protocol Number:  TROV-052 
Study Phase:  1b/2  
Product Name:  Onvansertib (PCM-075) 
IND Numb er: 135237 
Sponsor:  Trovagene, Inc. 
11055 Flintkote Avenue 
San Diego, CA 92121 
 
 
Issue Date:  07 Aug  2019 
Amendment Number:  Amendment 2 
Protocol Version:  Version 6.0 
Prior Protocol Version:  Version 5.0, dated 16 May  2018 
This study will be performed in compliance with Good Clinical Practice (GCP), the 
Declaration  of Helsinki (with amendments), and local legal and regulatory requirements.  
CONFIDENTIAL  
T
his document and its contents are the property of and confidential to T rovagene, Inc. 
(hereinafter referred to as Trovagene). Any unauthorized copying or use of this 
document is  prohibited. 

 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 2 of 83 
CONFIDENTIAL  2 TABLE OF CONTENTS  
 
1 CLINICAL STUDY PROTOCOL  .......................................................................................1  
2 TABLE OF CONTENTS  ......................................................................................................2  
3 SYNOPSIS  ............................................................................................................................8  
4 LIST OF ABBREVIATIONS  .............................................................................................20  
5 ADMINISTRATIVE STRUCTURE  ..................................................................................23  
6 INTRODUCTION  ..............................................................................................................24  
6.1 Background ......................................................................................................................24  
6.1.1  Acute Myeloid Leukemia ...................................................................................24  
6.1.2  Polo- like Kinase 1  ...............................................................................................25  
6.1.3  Onvansertib (PCM-075) .....................................................................................25  
6.2 Study and Dose Rationale ................................................................................................29  
6.3 Risks and Benefits for Subjects ........................................................................................29  
7 STUDY OBJECTIVES  .......................................................................................................30  
7.1 Primary Ob jectives  ...........................................................................................................30  
7.2 Secondary Objectives  .......................................................................................................30  
7.3 Exploratory Objectives .....................................................................................................30  
8 INVE STIGATIONAL PLAN  .............................................................................................31  
8.1 Overall Study Design and Plan  ........................................................................................31  
8.1.1  Phase 1b  ..............................................................................................................31  
8.1.1.1  Combination Treatment Arms  ........................................................................... 31  
8.1.1.2  Dose Escalation .................................................................................................. 32  
8.1.1.3  Preliminary Safety and Efficacy Assessment  .................................................... 33  
8.1.2  Phase 2  ................................................................................................................34  
8.1.3  Study Endpoint s ..................................................................................................34  
8.2 Study Duration  .................................................................................................................35  
8.3 Eligibility Criteria  .............................................................................................................35  
8.3.1  Inclusion Criteria  ................................................................................................36  
8.3.2  Exclusion Criteria  ...............................................................................................37  
8.3.3  Removal of Subjects from Therapy or Assessment  ............................................38  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 3 of 83 
CONFIDENTIAL  8.4 STUDY DRUG TREATMENT  .......................................................................................38  
8.4.1  Description of Study Treatments  ........................................................................38  
8.4.1.1  Onvansertib (PCM-075) .................................................................................... 38  
8.4.1.2  Cytarabine  .......................................................................................................... 40  
8.4.1.3  Decitabine  .......................................................................................................... 40  
8.4.2  Dosing Schedule .................................................................................................40  
8.4.3  Study Drug Inventory and Accountability ..........................................................41  
8.4.4  Treatment Compliance  ........................................................................................41  
8.4.5  Concomitant Medications and Treatments .........................................................41  
9 ASSESSMENTS  .................................................................................................................43  
9.1 Schedule of Assessments  ..................................................................................................43  
9.2 Study Visits  ......................................................................................................................54  
9.2.1  Phase 1b  ..............................................................................................................54  
9.2.1.1  Pretreatment Evaluations (Screening and Baseline)  .......................................... 54  
9.2.1.2  Evaluations During Treatment ........................................................................... 55  
9.2.1.3  Post-Treatment Evaluations (Follow-up/End of Study) .................................... 56  
9.2.2  Phase 2  ................................................................................................................56  
9.2.2.1  Pretreatment Evaluations (Screening and Baseline)  .......................................... 56  
9.2.2.2  Evaluations During Treatment ........................................................................... 57  
9.2.2.3  Post- treatment Evaluations (Follow -up/End of Study) ...................................... 58  
9.3 Efficacy Assessments  .......................................................................................................59  
9.3.1  Efficacy Variables ...............................................................................................59  
9.3.1.1  Morphologic Leukemia -free State  ..................................................................... 59  
9.3.1.2  Complete Response............................................................................................ 59  
9.3.1.3  Complete Response with Incomplete Blood Count Recovery........................... 59  
9.3.1.4  Partial Response ................................................................................................. 59  
9.3.1.5  Duration of Response......................................................................................... 60  
9.3.1.6  Event- free Survival  ............................................................................................ 60  
9.3.1.7  Overall Survival ................................................................................................. 60  
9.4 Safety Assessments  ..........................................................................................................60  
9.5 Pharmacokinetic Assessments  ..........................................................................................60  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 4 of 83 
CONFIDENTIAL  9.6 Pharmacodynamic and Biomarker Evaluation  .................................................................61  
10 ADVERSE EVENT REPORTING .....................................................................................61  
10.1  Definitions  ........................................................................................................................61  
10.1.1  Adverse Event  .....................................................................................................61  
10.1.2  Unexp ected Adverse Events ...............................................................................61  
10.1.3  Serious Adverse Event ........................................................................................61  
10.1.4  Definition of Dose- limiting Toxicities  ...............................................................62  
10.1.5  Determination of the Maximum Tolerated Dose  ................................................63  
10.2  Severity of Adverse Events ..............................................................................................63  
10.3  Relationship of Adverse Events to the Study Drug ..........................................................63  
10.4  Monitoring of Adverse Events .........................................................................................64  
10.5  Reporting Procedures .......................................................................................................64  
10.5.1  Routine Reporting of Adverse Events ................................................................64  
10.5.2  Reporting of Serious Adverse Events, Including Death .....................................65  
10.5.3  Other Events Requiring Immediate Reporting  ...................................................66  
10.5.3.1  Overdose ............................................................................................................ 66  
10.5.3.2  Pregnancy ........................................................................................................... 66  
11 SUBJECT DISCONTINUATION AND TRIAL DISCONTINUATION  .........................68  
11.1  Subject Discontinuation ...................................................................................................68  
11.2  Study Discontinuation ......................................................................................................68  
12 STATISTICAL METHODS  ...............................................................................................69  
12.1  Dosin g Algorithm and Determination of Sample Size  .....................................................69  
12.2  Statistical Analysis of Safety Data  ...................................................................................69  
12.3  Statistical Analysis of Efficacy Data  ................................................................................70  
13 ACCESS TO SOURCE DOCUMENTS AND RETENTION OF RECORDS  ..................71  
14 QUALITY CONTROL AND QUALITY ASSURANCE  ..................................................72  
14.1  Data Collection  .................................................................................................................72  
14.2  Study Monitoring .............................................................................................................72  
14.3  Data Management  .............................................................................................................73  
14.4  Sponsor Audits .................................................................................................................73  
14.5  Inspection by Regulatory Authorities ...............................................................................73  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 5 of 83 
CONFIDENTIAL  15 ETHICS ...............................................................................................................................74  
15.1  Declaration of Hels inki ....................................................................................................74  
15.2  Good Clinical Practice and Regulatory Compliance  ........................................................74  
15.3  Institutional Review Board/Independent Ethics Committee  ............................................74  
15.4  Informed Consent .............................................................................................................74  
15.5  Emergency Departure from Protocol ...............................................................................75  
16 PUBLICATION POLICY  ..................................................................................................76  
17 PROTOCOL AMENDMENTS AND MODIFICATIONS  ................................................77  
18 REFERENCES  ...................................................................................................................78  
19 APPENDICES:  ...................................................................................................................80  
19.1  Appendix 1: National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03 .........................................................................................81  
19.2  Appendix 2: New York Heart Association Functional Classification .............................81  
19.3  Appendix 3: ECOG Performance Status ..........................................................................82  
19.4  Appendix 4: Package Insert for Cytarabine and Dacogen™ (Decitabine).......................82  
19.5  Appendix 5: Clinical Study Report PLKA-937-001 ........................................................82  
19.6  Appendix 6: Torsades de Pointes Risk QT Interval Normogram ....................................83  
 
LIST OF TABLES  
Table 6 -1: Drug -related Treatment -emergent AEs  ....................................................................... 28  
Table 8 -1: Onvansertib (PCM-075) Dose and Dosing Levels ...................................................... 33  
Table 9 -1: Schedule of Events: Phase 1b Cycle 1 ........................................................................ 44  
Table 9 -2: Schedule of Events: Phase 1b Cycle ≥2  ...................................................................... 47  
Table 9 -3: Schedule of Events: Phase 2 (all cycles)  ..................................................................... 50  
 
  
DocuSign Envelope ID: A731D39D -A6AA-467E-9971-3FA6F4C76176 
®o •trovagene
ONCOlOCY 
Onvansertib (PCM-075) TROV-052 
Clinical Study Protocol 
Amendment 2, Version 6.0 
07 Aug 2019 
A Phase lb/2 Study of Onvansertib (PCM-075) in Combination with Either Low-dose 
Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML) 
 
 
 
Signature 
CONFIDENTIAL PROTOCOL APPROVAL IGNATURES 
Trovagene, Inc. 
Chief Executive Officer 
Title 
8/12/2019 
Date 
Chief Scientific Officer 
Title 
8/12/2019 
Date 
Vice President, Scientific Services 
PRA Health Sciences 
Title 
-Date
Page 6 of 83 

 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 7 of 83 
CONFIDENTIAL   
INVESTIGATOR SIGNATURE PAGE  
 
Protocol No:  TROV -052 
Protocol Version:  Amendment 2, Version 6.0 
Protocol Date:  07 Aug 2019 
Protocol Title:  A Phase 1b/2 Study of Onvansertib ( PCM -075) in Combination with Either Low-dose 
Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML)  
I have read the attached protocol and hereby agree that it contains all the necessary details for 
perform ing the Product Study.  
I will provide copies of the protocol to the Investigational Review Board and all members of the Study team responsible to me who participate in the Study. I will discuss this material with them 
to ensure that all participating personnel at the Study site are fully informed regarding the 
investigational device and the conduct of the protocol.  
Once the Investigational Review Board approves the protocol, I will not modify this protocol 
without obtaining the prior approval of both the Sponsor and the Investigational Review Board. 
I will submit the protocol modifications and/or any informed consent modifications to the Sponsor and the Investigational Review Board, as applicable, and approval will be obtained before any modifications are implemented.  
   
Investigator's Signature   Date  
   
Investigator’s Printed Name    
   
Study Site Name    
   
Address    
 
City, State, Zip Code, Country  
 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 8 of 83 
CONFIDENTIAL  3  SYNOPSIS  
 
Protocol Title:  A Phase 1b/2 Study of Onvansertib ( PCM -075) in Combination with E ither 
Low-dose Cytarabine or Decitabine in Subjects with Acute Myeloid 
Leukemia (AML)  
Protocol Number:  TROV -052 
IND Number: 135237 
Number of Study Sites:  This study is being  conducted at 8 study centers.  
Phase:  1b/2 
Objectives:  Primary Objectives  
Phase 1b:  
• To evaluate the dose limiting toxicities (DLTs) and maximum 
tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of 
onvansertib ( PCM -075) in combination with either low -dose 
cytarabine or decitabine in subjects with AML  
Phase 2:  
• To assess the safety and tolerability of the combination of either onvansertib ( PCM -075) at the MTD (or RP2D)  and low -dose 
cytarabine or the combination of onvanser tib (PCM -075) at the MTD 
(or RP2D)  and decitabine in  subjects with AML  
• To evaluate the preliminary anti- leukemic activity of the combination 
of either onvansertib ( PCM -075) at the MTD (or RP2D)  and low -dose 
cytarabine or the combination of onvansertib ( PCM -075) at the MTD 
(or RP2D)  and decitabine in subjects with AML  
Secondary Objectives  
Phase 1b:  
• To assess the incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI -CTCAE) (version 4.03) of onvansertib 
(PCM -075) in combination with either low -dose cytarabine or 
decitabine in subjects with AML  
• To analyze the pharmacokinetics (PK) of onvansertib ( PCM -075) 
when given i n combination with either low -dose cytarabine or 
decitabine in subjects with AML  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 9 of 83 
CONFIDENTIAL  Phase 2:  
• To assess the incidence and severity of AEs according to the 
NCI-CTCAE version 4.03 of onvansertib ( PCM -075) in combination 
with either low -dose cytarabine or decitabine in subjects with AML  
• To analyze the PK of onvansertib ( PCM -075) when given in 
combination with either low -dose cytarabine or  decitabine in subjects 
with AML  
Exploratory Objectives  
Phase 1b and Phase 2: 
• To explore additional analyses evaluating potential pharmacodynamic 
(PD)  and diagnostic biomarkers of onvansertib ( PCM -075) in subjects 
with AML  
Study Design:  This is a Phase 1b/2, open- label study of the safety and anti -leukemic 
activity of onvansertib in combination with either low- dose cytarabine or 
decitabine in subjects with AML.  
In Phase 1b, subjects will have relapsed or refractory disease and must have received no more than 3 prior regimens for the treatment of their AML. 
Subjects may be treatment naïve as long as they are not candidates for or have refused intensive induction therapy.  
In Phase 2, subjects must have received no more than 1 prior regimen for the 
treatment of their AML. Subjects may be treatment naïve as long as they are not candidates for or have refused intensive induction therapy.   
In both phases, prior treatment with either low- dose cytarabine or decitabine 
for myelodysplastic syndromes ( MDS ) will not be considered a prior 
regimen. For subjects who have undergone hematopoietic stem cell 
transplantation, the preparative (conditioning) regimen and transplant will be considered to be a single line of prior therapy.  
Phase 1b:  
Subjec ts in Phase 1b will receive either a combination of onvansertib and 
low-dose cytarabine, or a combination of onvansertib and decitabine in 
2 separate arms using a standard 3+3 design in each arm.  
In Arm A, onvansertib  will be administered in escalating dos es orally ( p.o.) 
Day 1 through Day 5 every 21 to 28 days in combination with cytarabine, 
which will be administered in all cohorts as 20 mg/m2 subcutaneously (SC) 
once daily on Day 1 through Day 10 every 28 days. Onvansertib 
administration, in combination with cytarabine, will be initiated at a starting 
dose of 12 mg/m2 p.o. daily for 5 days (Dose Level 0). On days where both 
agents are administered ( Days 1 -5), cytarabine will be administered first 
followed by onvansertib . Investigator assessment of subject s may allow them, 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 10 of 83 
CONFIDENTIAL  at their discretion, to treat more frequently  than every 21 to 28 days; however, 
in no case may a cycle length be less than 21 days.  
In Arm B, onvansertib will be administered in escalating doses p.o. Day 1 
through Day 5 every 21 to 28 days in combination with decitabine, which will 
be administered consistently in all cohorts as 20 mg/m2 intravenously (IV) 
over 1 hour on Day 1 through Day 5 every 28 days. On vansertib 
administration, in combination with decitabine, will be initiated at a starting 
dose of 12 mg/m2 p.o. daily for 5 days (Dose Level 0). The daily dose of 
decitabine will be administered first followed by onvansertib. Investigator 
assessment of sub jects may allow them, at their discretion, to treat more 
frequently than every 21 to 28 days; however, in no case may a cycle length 
be less than 21 days.  
The first 3 subjects will be allocated to Arm A (Cohort A1). If Cohort A1 is expanded to 6 subjects prior to the first subject being enrolled in Arm B, then enrollment in Cohort A1 will be completed before enrollment begins in 
Arm B. After all subjects are enrolled in Cohorts A1 and B1, subjects will 
enroll in subsequent dose escalation cohorts based on t he following decision 
rules:  
• If Arm A is open for enrollment, subjects will enroll in the open Arm A 
cohort regardless of dose level  
• If Arm A is closed to enrollment, subjects will enroll in the open Arm B 
cohort regardless of dose level  
Dosing in Arms A a nd B will proceed independently. Each arm will follow a 
standard 3+3 dose -escalation design in which the onvanser tib dose will be 
escalated by 50% increments in successive cohorts of 3 subjects. If none of 
the 3 subjects enrolled at any dose level experience a DLT, the dose of onvansertib will be escalated by 1 dose level in each successive cohort. If 
1 subject in the f irst 3 experiences a DLT, up to 3 additional subjects will be 
enrolled at that dose level. If there are no additional DLTs ( ie, ≤1 of 
6 subjects with DLT), then dose escalation will again proceed. If there are 
2 subjects who experience DLTs among the first 3 subjects enrolled, or there is a second DLT in up to 6 subjects enrolled at any dose level, the MTD will 
be judged to have been exceeded, and no additional subjects will be started at 
that dose. The MTD will then be established at a prior dose level or an 
additional cohort may be enrolled at an intermediate dose level upon 
agreement with the Sponsor, Medical Monitor, and Principal Investigator.  
The RP2D can be determined based on the assessment of safety, PK, PD, and 
preliminary efficacy of subjects treated at a  dose level that has been cleared 
for safety , regardless of whether or not an MTD has been reached . In this 
case,  no further dose escalation will be done to determine an MTD.  
Each cohort will be evaluated for toxicity, recovery of blood counts, and PK. 
DLTs will be evaluated for the first 28 days after initiation of therapy. In the 
case of pancytopenia present at Day 28 in the absence of other toxicity that 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 11 of 83 
CONFIDENTIAL  constitutes a DLT, the duration for DLT evaluation will be extended to 
42 days (unless the pancytopenia resolves between Day s 28 and 42, or is 
determined to be due to persistent leukemic involvement of the bone marrow 
or another cause unrelated to study therapy). Pancytopenia , related to 
onvansertib in the absence of another cause unrelated to study therapy that 
persists beyond Day  42, will be considered a DLT. If an I nvestigator elects to 
re-treat a subject prior to 28 days (allowed no sooner than on Day  22), the 
DLT evaluation period will end at the time of initiation of the second cycle of therapy. 
Dose modifications and delays for safety will be performed as described in the protocol. After the first cycle, additional cycles can be administered to 
indivi dual subjects based on Investigator judgment, if hemato poietic recovery 
is documented, and may incorporate delays or supportive care until hematopoietic function returns to baseline or Grade ≤1, as long as the subject is receiving clinical benefit without safety or tolerability issues. In the case 
that failure to achieve hematopoietic recovery is judged to be related to 
persistent leukemic involvement in the bone marrow, I nvestigators may re -
initiate therapy according to their clinical judg ment  upon discussion with the 
Medical Monitor .  
Investigators will also have the option for intra- subject dose escalation in 
later cycles if safety and tolerability have been demonstrated at higher doses 
of onvansertib. 
At any time during Phase 1b, the Sponsor , in consultation with the Safety 
Review Committee (SRC) , may elect to discontinue enrollment into either 
arm of the study based on safety , efficacy , PK, and PD  considerations. In this 
case, enrollment in the other arm will continue as described.  
Following assessment of safety and preliminary efficacy in the first 5 dose 
level escalation cohorts (0 : 12 mg /m
2; +1: 18 mg /m2; +2: 27 mg /m2; 
+3: 40 mg/m2; +4: 60 mg /m2) in both Arm A (onvansertib in combination 
with low -dose cytarabine) and Arm B (onvansertib in combination with 
decitabine), the decision was made to discontinue Arm A from further dose escalation and subject enrollment.  
Arm B will continue forward with  dose escalation as outlined in the protocol, 
or until such time as the RP2D is determined at a dose level previously 
cleared for safety.   
Phase 2:  
In Phase 2, a total of 32 subjects  will be enrolled at the RP2D  to further 
evaluate safety and preliminary efficacy . Onvansertib will be administered 
p.o. on Day 1 through Day 5 every 21 to 28 days, in combination with 
decitabine, administered consistently as 20  mg/m2 IV over 1 hour on Day 1 
through Day 5 every 28 days, with treatment modifications or delays based 
on return of hematopoietic function to baseline or Grade ≤1 toxicity for 
optimal subject management. The daily dose of decitabine will be 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 12 of 83 
CONFIDENTIAL  administered first followed by onvansertib. Investigator assessment of 
subjects may allow them, at their discretion, to treat more frequently than 
every 28 days; however, in no case may a cycle length be less than 21 days. 
Subjects may continue treatment in the study at any dose until clinically 
significant disease progression or death, unaccep table toxicity, withdrawal of 
consent, or discontinuation based on Investigator discretion. Any subject becoming pregnant while on the study should be withdrawn from treatment 
but will remain in the study. After obtaining the subject’s consent (or subject 
and pregnant partner’s consent in the case of a male participant), monitoring of the pregnancy should continue until conclusion of the pregnancy. Each 
subject will be followed for survival for up to 1 year after enrollment. 
AEs and concomitant medication u se will be queried, monitored, and 
recorded throughout the study. Safety evaluations will include: physical 
examinations, performance status, vital signs, electrocardiograms (ECGs), 
hematology, and serum chemistry laboratory tests and urinalysis.  
Sample Size:  Phase 1b: up to 84 subjects (42 in each arm), dependent on the number of dose escalation cohorts required to determine the MTD or RP2D   
Phase 2: 32 subjects  at the RP2D  
Total: up to 116 subjects  
Endpoints:  Primary safety endpoints:  
1. Characterization of DLTs; characterization of Aes by type, incidence, 
severity (graded by NCI -CTCAE version 4.03), seriousness, and 
relationship to treatment effects on vital signs and laboratory parameters; 
and changes from baseline in ECGs, p hysical examinations, weight, and 
ECOG performance status  
Primary efficacy endpoint:  
1. Rate of complete response (CR + C ri) in Phase 2, defined as a 
morphologic leukemia- free state (MLF; see below) plus:  
For CR:  
a. Subject is independent of transfusions  
b. Absolute neutrophil count (ANC) of >1000/mm3 
c. Platelets of ≥100,000/mm3 
For C ri: 
1. Meets all criteria  for CR except for either neutropenia (ANC 
<1000/mm3) or thrombocytopenia (<100,000/mm3) but must 
include transfusion independence 
Secondary endpoints: 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 13 of 83 
CONFIDENTIAL  1. Rate of achievement of a MLF in Phase 2, defined as:  
a. Bone marrow (BM) <5% blasts in an aspirate with spicules (a BM 
biopsy should be performed if spicules are absent) 
b. No blasts with Auer rods or persistence of extramedullary disease  
2. Rate of partial response (PR) in Phase 2: All of the hematologic values 
for a CR but with a decrease of at least 50% in the percentage of blasts to 
5% to 25% in the bone marrow aspirate and a normalization of blood 
counts as noted above 
3. Duration of response (DOR) in Phase 2: Time from documentation of 
response until documentation of recurrence of or progression of disease  
4. Event -free survival (EFS) in Phase 2: Time from enrollment until disease 
progression or de ath from any cause  
5. Overall survival (OS) in Phase 2: Time from enrollment until death from 
any cause  
6. Concentrations of onvansertib in plasma samples collected at pre-
specified time points before and after administration of onvansertib, 
including maxi mum plasma concentration (C max), trough plasma 
concentration (C min), time to maximum plasma concentration (T max), area 
under the plasma concentration versus time curve (AUC), and plasma 
terminal elimination half -life (t 1/2) 
Exploratory endpoints: 
1. Blood sam ples for PD  and diagnostic biomarker evaluation  
2. Evaluation of the rate of complete response (CR + CRi), MLF, PR, DOR, EFS and OS in all enrolled subjects (Phases 1b and 2)  
Indication:  Acute myeloid leukemia (AML)  
Diagnosis and Main 
Eligibility Criteria: Subjects who meet all of the following inclusion criteria and none of the exclusion criteria will be eligible to be enrolled in the study. 
Inclusion Criteria: 1. Disease Status and Prior Therapy:  
a. Histologically confirmed diagnosis of AML  
b. Phase 1b:  
i. Subjects with relapsed or refractory AML who have received no 
more than 3 prior treatment regimens for AML. Subjects who have received prior treatment with cytarabine or decitabine are not 
excluded. Prior treatment with either low -dose cytarabine or 
decitabine given for MDS will not be considered a prior regimen. 
For subjects w ho have undergone hematopoietic stem cell 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 14 of 83 
CONFIDENTIAL  transplantation, the preparative (conditioning) regimen and 
transplant will be considered to be a single line of prior therapy. 
OR 
ii. Subjects who are treatment naïve and are not candidates for or have 
refused intensi ve induction therapy. 
c. Phase 2:  
i. Subjects with relapsed or refractory AML who have received no 
more than one prior treatment regimen for AML. Subjects who have 
received prior treatment with decitabine are not excluded. Prior 
treatment with decitabine given for MDS will not be considered a 
prior regimen.   
OR 
ii. Subjects who are treatment naï ve and are not candidates for or have 
refused intensive induction therapy.  
2. Age ≥18 years  
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 
(Appendix19.3 ) 
4. Subjects must be willing and able to review, understand, and provide written consent before starting any study- specific procedures or therapy  
5. All men and women must agree to practice effective contraception during the entire study period and after discontinuing study drug, unless documentation of infertility exists, as follows:  
a. Sexually active, fertile women must use 2 effective forms of 
contraception (abstinence, intrauterine device, oral contraceptive, or 
double barrier device) from the time of informed consent and until at least 6 months after discontinuing study drug 
b. Sexually active men and their sexual partners must use effective contraceptive methods from the time of subject informed consent and until at least 3 months after discontinuing study drug 
Exclusion Criteria: 
1. Treatment -related AML or acute promyelocytic leukemia (APL)  
2. Active malignancies within the last 12 months with the exception of those 
with a negligible risk of metas tasis or death  
3. Clinical evidence of active central nervous system leukemia at the time 
of screening 
4. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2.5 x upper limit of normal (ULN).  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 15 of 83 
CONFIDENTIAL  5. Total bilirubin >2.0  mg/dL (or >3.0  mg/dL in subjects with documented 
Gilbert syndrome)  
6. Serum creatinine ≥2.0 mg/dL  
7. New York Heart Association (NYHA) Class III or IV heart disease 
(Appendix 19.2), active ischemia or any other uncontrolled cardiac 
condition, or hypertensive or metabolic condition 
8. Myocardial infarction in the previous 12 weeks (from the start of 
treatment)  
9. Resting left ventricular ejection fraction <50% at the time of screening  
10. QT interval with Fridericia’s correction [QTcF] [16] >450 milliseconds for men, or >470 milliseconds for women. The QTcF should be 
calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of potentially correctible causes of QT prolongation ( eg, 
medications, hypokalemia), the triplicate ECG may be repeated once 
during screening and that result may be used to determine eligibility. 
11. Pregnant or breast feeding  
12. Active and uncontrolled disease (other than AML) or infection as 
judged by the treating physician 
13. Treatment with systemic therapy for the primary disease within 14 days 
of first dose (except for hydroxyurea or isolated doses of cytarabine or 
decitabine for white blood cell control) 
 
14. Grade 2 or greater toxicities from prior therapy, except for Grade 2 toxicities that are not expected to resolve and that in the judgment of the 
Investigator do not pose a significant safety risk to subject participation.  
15. Subjects with any other medical condition, including mental illness or 
substance abuse, deemed by the Investigator to be likely to interfere with 
the subject’s ability to sign the informed consent form or his/her ability to 
cooperate and participate in the study, or to interfere with the 
interpretation of the results.  
Test P roduct, Dose, 
and Mode of 
Administration:  Onvansertib ( PCM -075): The Phase 1b onvansertib starting dose is 
12 mg/m2 (Dose Level 0) administered p.o. on Day 1 through Day 5 every 28 
days. Dose escalation is discussed in  detail in the protocol. In Phase 2, 
onvansertib will be administered at the MTD (or RP2D) p.o. on Day 1 
through Day 5 every 21 to 28 days. Investigator assessment of subjects may 
allow them, at their discretion, to treat more frequently  than every 28 days; 
however, in no case may a cycle length be less than 21 days. Day 1 of 
onvansertib therapy should always be Day 1 of either cytarabine or decitabine 
therapy in all cycles.  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 16 of 83 
CONFIDENTIAL  Cytarabine : 20 mg/m2 SC once daily on Day 1 through Day 10 every 
28 days in Phase 1b.  On days where both agents are administered (D ays 1 -5), 
cytarabine will be administered first followed by onvansertib. 
Decitabine : 20 mg/m2 IV over 1 hour on Day 1 through Day 5 every 21 to 
28 days in Phase 1b.  Based on the  RP2D  combination determined in 
Phase 1b, decitabine will be given in combination with onvansertib in 
Phase 2. The daily dose of decitabine will be administered first follow ed by 
onvansertib.  
Efficacy Evaluation: Efficacy Assessments  
All subjects evaluable for anti -leukemic activity will be assessed for 
response to treatment using the recommendations of the International Working Group (IWG) for standardization of response criteria, treatment 
outcomes, and reporting for therapeutic trials. [ 17
] The primary efficacy 
variable is leukemia responses, evaluated by the Investigator based on bone 
marrow aspirate and peripheral blood examination.  
Efficacy Endpoints [ 18]: 
1. Morphologic leukemia -free stat e 
a. BM <5% blasts in an asp irate with spicules (a BM biopsy should be 
performed if spicules are absent)  
b. No blasts with Auer rods or persistence of extramedullary disease  
2. Complete response (CR):  
a. Morphologic leukemia -free state plus:  
i. Subject is independent of transfusions  
ii. Absolute neutrophil count (ANC) of >1000/mm3 
iii. Platelets of ≥100,000/mm3 
3. Complete response with incomplete blood count recovery (CRi) meets 
all criteria for CR except for either neutropenia (ANC <1000/mm3) or 
thrombocy topenia (<100,000/mm3) but must include transfusion 
independence 
4. Partial response (PR): All of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate and a normalization of blood counts as noted 
above 
5. Duration of response (DOR): Time from documentation of response until documentation of recurrence of or progression of disease  
6. Event -free survival (EFS): Time from enrollment until disease 
progression or death from any cause 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 17 of 83 
CONFIDENTIAL  7. Overall survival (OS): Time from enrollment until death from any cause  
Safety Evaluation: Toxicity will be graded using the NCI-CTCAE version 4.03  
1. Safety analyses will be conducted on all subjects who have received at 
least 1 dose of study drug, and will include the frequency of all AEs and 
laboratory abnormalities as well as the frequency of dose interruptions, 
dose reductions, and treatment discont inuations. All AEs must be 
attributed to study drugs unless there is a reasonably acceptable 
alternate cause for the AEs. 
2. In each phase of the study, DLTs will be considered to be any non-hematologic Grade 3 abnormalities that persist >7 days without 
decreasing in severity despite standards of care, are clinically significant, or that are Grade 4 and symptomatic. Exceptions and additional 
parameters for assessment of non -hematologic DLT are provided in the 
protocol. For hematologic toxicities, only persiste nt pancytopenia 
resistant to current standards of care that continues for ≥42 days and is 
not related to leukemic infiltration or another cause judged to be unrelated to study therapy will be considered as a DLT, since marrow 
aplasia is an expected consequence of AML therapy.  
3. Additional safety assessments will include physical examination; medical history; ECG; ECOG performance status; weight; vital signs 
measurements; clinical laboratory testing (hematology, clinical chemistry, and urinalysis) and multigated acquisition (MUGA) or 
echocardiography (ECHO) scans  
Safety Monitoring: The SRC consisting of the Principal Investigators and Medical Monitor, will monitor subjects for safety and evaluate the efficacy of onvansertib doses to 
minimize exposure of subjects to a non- efficacious dose level.  
Pharmacokinetic Evaluation: Blood samples for PK  analysis of onvansertib will be collected pre -dose, and 
0.5, 1, 2, 3, 4, 8, (±10 minutes) and 24 hours (± 1 hour ) after administration of 
onvansertib on Day 1 and Day 5, as well as once each on Days 8, 15 , and 22 
(Cycle  1 only). For Cycle  2, blood samples for PK analysis should be 
collected, if feasible, pre-dose, 3 hours, and 24 hours (all ±10 minutes) after 
admini stration of onvansertib on Days 1 and 5, and once each on Days 8, 15, 
and 22. 
Pharmacodynamic and 
Diagnostic Biomarker 
Evaluation: Pharmacodynamic and diagnostic biomarker analysis will be obtained, if 
feasible, pre-dose, 3 hours (±10 minutes), and 24 hours (± 1 hour ) after 
administration of onvansertib on Days 1 and 5, and once each on Days 8, 15, 
and 22 ( Cycles 1-3). For Cycle 4 and beyond, samples will be collected on 
Days 1 (pre- dose) and 15. The schedule for obtaining these may be amended 
based on results of prior evaluations. 
Statistical Methods:  Safety Analysis:  
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 18 of 83 
CONFIDENTIAL  Safety assessment data for all subjects who receive at least one do se of study 
drug will be listed and summarized and will include data from AEs and 
concomitant medication queries, physical examination findings, ECOG 
performance status, weight and vital signs measurements, ECG 
measurements, and clinical laboratory testing  (hematology, clinical 
chemistry, and urinalysis) values. Descriptive statistics will be generated as appropriate ( eg, mean, median, range, and SD  for continuous data; and 
frequency for categorical data).  
Efficacy Analysis: 
Data from all subjects who receive at least 1 dose of onvansertib in 
combination therapy will be included in the intention -to-treat (ITT) efficacy 
analysis. Subjects completing at least 1 cycle of treatment will be included in 
the per protocol efficacy analysis.  
Descriptive statistics will be generated as appropriate ( ie, mean, median, 
range, and SD ). Median survival statistics will be estimated using the 
Kaplan -Meier method. 
The primary efficacy endpoint is the rate of CR + CRi in the Phase 2 portion of the study. Based on a population CR + CRi rate of 20% for either the 
combination of cytarabine plus onvansertib or decitabine plus onvansertib, with 32 evaluable patien ts in the primary analysis the 90% CI for the 
CR + CRi rate from the study will have an estimated precision of approximately 58% and width 0.23, and a 95% CI would have an estimated 
precision of approximately 70% and width 0.28. 
Pharmacokinetic Analysis : 
PK parameters of the population defined in the Statistical Analysis Plan will 
include maximum concentration (C
max), time of maximum concentration 
(Tmax), area under the curve over the first 24 hours (AUC 0-24), and drug 
elimination half -life (t 1∕2), which will be estimated from plasma concentration 
data. The geometric mean and 95% CI s will be reported for all evaluable 
subjects.  
Sample Size Rationale : Exposure of any subject at the starting dose, based on prior experience with 
this drug in patients with solid tumors (Section 6.1.3) with exclusive ly 
hematologic toxicities that are required in the treatment of patients with 
AML, is reasonable in Phase 1b for a dose that has the potential for efficacy 
based on preclinical modeling. The 3+3 design will allow a dose with a ≥50% 
probability of causing a DLT to have at most a 12.5% chance of satisfying the 
conditions for dose escalation after the first 3 subjects and a ≥50% chance of 
stopping at 3. With 6 subjects, there is at most a 17.2% chance of satisfying 
the conditions for dose escalation after 6 subjects.  
Phase 2 will proceed with  a total of 32 subjects  at the identified RP2D ; 
however, if at any time during this phase more than 33% of subjects develop 
 TROV -052 
 Clinical Study Protocol  
 Amendment 2, Version 6.0  
Onvansertib (PCM -075) 07 Aug 2019  
 
Page 19 of 83 
CONFIDENTIAL  a DLT -level AE (as per protocol), accrual will stop and the RP2D  will be 
reassessed in additional cohorts.  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
 
CONFIDENTIAL  Page 20 of 82 4 LIST OF ABBREVIATION S 
Abbreviation  Definition  
AE Adverse Event  
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase  
AML  Acute Myeloid Leukemia  
ANC  Absolute Neutrophil Count  
APC/C  Anaphase -promoting Complex/ Cyclosome  
APL  Acute Promyelocytic Leukemia  
ASCO  American Society of Clinical Oncology  
ASH  American Society of Hematology  
AST  Aspartate Aminotransferase  
AUC  Area under the plasma concentration vs time curve  
BM Bone Marrow  
BSA  Body Surface Area  
BUN Blood Urea Nitrogen  
CBC  Complete Blood Count  
CFR  Code of Federal Regulations  
Cmax Maximum plasma concentration  
Cmin Trough plasma concentration  
CR Complete Response  
CRF  Case Report Form  
CRi Complete Response with Incomplete Blood Count Recovery  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  Dose -limiting Toxicity  
DOR  Duration of Response  
ECG  Electrocardiogram  
ECHO  Echocardiography  
ECOG  Eastern Cooperative Oncology Group 
eCRF  Electronic CRF  
EFS Event -free Survival  
EOS  End of Study 
FDA  Food and Drug Administration 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 21 of 83 
CONFIDENTIAL  Abbreviation  Definition  
GCP  Good Clinical Practice  
HI Hematologic Improvement  
HIPAA Health Insurance Portability and Accountability Act  
HMA Hypomethylating Agent  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmoni sation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
INR International Normalized Ratio  
IRB Institutional Review Board  
ITT Intention -to-Treat  
IV Intravenous(ly)  
IWG  International working group  
LDAC  Low-dose Ara -C 
LDH  Lactate Dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
MDS  Myelodysplastic Syndromes  
MLF  Morphologic Leukemia -Free State  
MTD  Maximum Tolerated Dose  
MUGA Multigated Acquisition Scan 
NCI National Cancer Institute  
NYHA New York Heart Association  
OS Overall Survival  
PD Pharmacodynamics  
PHI Protected Health Information  
PK Pharmacokinetics  
PLK1  Polo-Like Kinase 1  
p.o. Orally or By Mouth  
PR Partial Response  
RP2D  Recommended Phase 2 Dose 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 22 of 83 
CONFIDENTIAL  Abbreviation  Definition  
QT Interval from the beginning of the QRS complex to the end of the T wave on an 
electrocardiogram  
QTcF  QT interval with Fridericia’s correction  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SC Subcutaneous(ly)  
SCT Stem Cell Transplant  
SEER  Surveillance, Epidemiology , and  End Results  
SRC  Safety Review Committee  
t1/2 Half-life 
Tmax Time to maximum plasma concentration  
TdP Torsade de pointes  
ULN  Upper Limit of Normal  
  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 23 of 83 
CONFIDENTIAL  5 ADMINISTRATIVE STRUCTURE  
Coordinating Investigator:   
Contract Research Organization (CRO):  PRA Health Sciences  
Medical Monitor:  
  

 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 24 of 83 
CONFIDENTIAL  6 INTRODUCTION  
6.1 Background 
6.1.1 Acute Myeloid Leukemia  
Acute myeloid leukemia ( AML) is a hematologic malignancy in which myeloid lineage cells of 
the bone marrow cease to differentiate appropriately, resulting in a marked increase in the 
number of circulating immature blast cells. As a consequence, the counts of mature red blood 
cells, platelets, and normal white blood cells decline, causing fatigue, shortness of breath, bleeding, and increased susceptibility to infection.[ 1] The Surveillance, Epidemiology, and 
End Results (SE ER) program estimates the annual incidence rate of AML in the US to be 
approximately 21,000 cases in 2017.[ 2
] Rates of new AML cases have been rising an average 
of 3.1% each year over the last 10 years. The median age of AML diagnosis is 68 years of age, and approximately 45% of new diagnoses are among patients age 70 years or older. [
3] 
Treatment options for AML patients are limited and vary depending on the age and fitness of the patient.[ 4
] Typically, patients 60 to 65 years of age or younger undergo induction 
chemotherapy using a combination of the nucleoside analog cytarabine and an anthracycline (either daunorubicin or idarubicin), a regimen commonly referred t o as “7+3” because the 
administration of the therapies consists of 7 consecutive days of cytarabine intravenous (IV) 
infusion followed by 3 consecutive days of anthracycline IV bolus; each cycle of 7+3 therapy 
is 28 days in duration and can be repeated. Complete remission is defined as <5%  blast cells in 
the bone marrow, with recovery of neutrophils to ≥10
9/L and platelets to ≥100 x109/L within 
1 to 2 cycles of induction chemotherapy. Patients then have follow-up consolidation therapy with high -dose cytarab ine for 3 to 4 cycles and, when feasible, either an autologous or 
allogeneic stem cell transplant (SCT). Because of the intensity of this approach, induction 
therapy as a means to transplant is less frequently adopted for patients over 60 to 65 years of 
age, although patients over 60 to 65 years of age can be considered for transplant (usually with 
reduced intensity conditioning regimens) based on other factors suggesting that they will survive the treatment regimen. Thus, despite 7+3 having been the standa rd first -line treatment 
for AML for over 30  years, better therapies for all patients are urgently needed, and this need is 
particularly critical for elderly or frailer patients. [
5] 
As an alternative to the standard cytotoxic chemo therapy, older patients are most frequently 
treated with lower -intensity options including hypomethylating agents (HMAs), such as 
5’-azacitidine (Vidaza®) and decitabine ( DacogenTM) or antimetabolites such as cytosine 
arabinoside (also referred to as cytarabine or Ara- C) given at a low -dose commonly known as 
low-dose Ara-C (LDAC). These agents have demonstrated a survival benefit compared to best 
supportive care in elderly AML patients. However, when these drugs are used as single-agents, AML relapses are i nevitable and generally occur within 12 months. 
Clearly, new and better therapeutic options are urgently required for AML, supporting the current study exploring onvansertib ( PCM -075), a polo-like kinase 1 (PLK1) inhibitor, in 
patients with refractory or r elapsed AML.  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 25 of 83 
CONFIDENTIAL  6.1.2 Polo -like Kinase 1  
Polo- like kinase 1 is the most well characterized member of the 5 members of the family of 
serine/threonine protein kinases and strongly promotes the progression of cells through mitosis. 
PLK1 performs several important functions throughout mitotic (M) phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of 
cohesins from chromosome arms, the inactivation of anaphase- promoting complex/cyclosome 
(APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. [ 6
] It plays a key role in 
centrosome functions and the assembly of bipolar spindles. It also acts as a negative regulator of p53 family members leading to ubiquitination and subsequent degradation of p53/TP53, 
inhibition of the p73/TP73 mediated pro-apoptotic functions and phosphorylation/degradation of bora, a cofactor of Aurora kinase A. During the various stages of mitosis, PLK1 localizes to 
the centrosomes, kinetochores, and cen tral spindle. PLK1 is aberrantly overexpressed in a 
variety of human cancers including AML and is correlated with cellular proliferation and poor 
prognosis. [
7] The first PLK1 inhibitor, BI 2536, showed interesting clinical a ctivity in patients 
with relapsed and treatment refractory AML in an early clinical study, and its successor volasertib (also known as BI 6727) demonstrated a more favorable toxicity profile, as well as potent anti-leukemic activity as monotherapy and in combination with LDAC in heavily 
pretreated AML patients. [
8, 9, 10 ] In 2013, volasertib received a Breakthrough Therapy 
designation from the Food and Drug Administration (FDA) for its potential as a treatment for 
patients with untreated AML who are ineligible for intensive remission induction therapy.  
6.1.3 Onvansertib ( PCM -075) 
Onvansertib (also known as PCM-075 and NMS -1286937) is the first PLK1- specific ATP 
competitive inhibitor administered by oral route to enter clinical trials with proven antitumor 
activity in different preclinical models. [ 11, 12, 13 , 14, 15 ] The compound shows high potency 
in proliferation assays having low nanomolar activity on a large number of cell lines, both from 
solid as well as hematologic tumors. Onvansertib potently causes a mitotic cell- cycle arrest 
followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with a clear 
PLK1 -related mechanism of action at well tolerated doses in mice after oral administration. In 
addition, onvansertib shows activity in combination therapy with approved cytotoxic drugs, such as irinotecan, in which there is enhanced tumor regression in HT29 human colon adenocarcinoma xenografts compared to each agent alone, and shows prolonged survival of 
animals in a disseminated model of AML in combinatio n therapy with cytarabine. Onvansertib 
has favorable pharmacologic parameters and good oral bioavailability in rodent and nonrodent 
species, as well as proven antitumor activity in different nonclinical models using a variety of 
dosing regimens, which may potentially provide a high degree of flexibility in dosing 
schedules, warranting investigation in clinical settings. Onvansertib has several advantages 
over volasertib, including a higher degree of potency and specificity for the PLK1 isozyme, and oral bioavailability.  
To date, a single Phase 1 dose- escalation safety study with onvansertib has been completed  in 
adult subjects with advanced/metastatic solid tumors at a single study site in the US. The 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 26 of 83 
CONFIDENTIAL  primary objective of that study was to determine first- cycle dose- limiting toxicities (DLT) and 
maximum tolerated dose (MTD) of onvansertib administered p.o. for 5 consecutive days every 
3 weeks ( ie, 21-day treatment cycle) in adult subjects with advanced/metastatic solid tumors.  
Secondary objectives of the stud y were to define the safety profile of onvansertib, determine 
the pharmacokinetics (PK) of onvansertib in plasma (at the MTD), and document any antitumor activity.  
A total of 21 subjects were enrolled in the Phase 1 study, and 19 subjects were treated. Four 
dose levels were explored: 6 mg/m
2/day (4 subjects enrolled, 3 treated), 12 mg/m2/day 
(3 subjects treated), 24  mg/m2/day (6 subjects treated), 48 mg/m2/day (4 subjects enrolled, 
3 subjects treated), and 36  mg/m2/day (4 subjects treated).  
The PK  parameters of onvansertib showed that the systemic exposure to onvansertib was 
generally higher on Day 5 than after the first administration on Day 1, with a terminal half -life 
ranging between 20 to 30 hours. Following the second cycle of treatment, the systemic exposure appeared to be similar to that in the first cycle, suggesting comparable exposure to 
the onvansertib in the 2 treatment cycles.  
In onvansertib subjects with ≥1 on- treatment safety assessment (as of the cut -off date of 
18 D ec 2013), no DLT occurred at the first 3 dose levels of 6, 12, and 24 mg/m
2/day. No 
patients experienced myelosuppression of any grade, defined as thrombocytopenia, leukopenia, neutropenia, or thrombocytopenia, at the 6 mg/m
2 or 12 mg/m2 dose levels, and a single patient 
(1/6) developed thrombocytopenia at the 24 mg/m2 dose level. At the subsequent dose level of 
48 mg/m2/day, 2 of the 3 subjects treated developed a first- cycle DLT: in 1 subject, a decrease 
in platelets to Grade 4 and an absolute neutrophil count (ANC) to Grade 4 lasted >7 days, and 
both events were considered by the Investigator to be not related to onvansertib; in the second 
subject, who was also receiving opiates, Grade 3 constipation was judged by the Investigator to be possibly related to onvansertib. At the 48 mg/m
2/day dose level, the MTD was considered to 
have been exceeded and an intermediate dose level of 36  mg/m2/day was investigated.  
Four subjects were treated at the 36  mg/m2/day dose level. Two of the 4 subjects had DLT 
following 5 days of treatment with onvansertib: 
• One subject had DLT of thrombocytopenia Grade 4 (platelet count <25,000/mm3) and 
neutropenia Grade 4 (ANC <500/mm3 for >7 days). Vitamin K and platelet transfusions 
were given to treat thrombocytopenia, and granulocyte colony- stimulating factor was 
administered for neutropenia. The subject demonstrated complete recovery of neutrophil and platelet counts to within normal limits within 10 days.  
• In a second subject, a DLT of thrombocytopenia Grade 4 (platelet count <25,000/mm
3) 
was observed. Following platelet transfusion, the subject’s platelet level recovered to Grade 1.  
Treatment -emergent abnormalities in hematology tests included lymphopenia (84.2%, 36.8%; 
Grade 3 -4), neutropenia (52.6%, 21%; Grade 3 -4), anemia (36.8%, 10.5%; Grade 3 -4), 
thrombocytopenia (31.6%, 15.8%; Grade 3 -4) and leukopenia (26.3%, 21.0%; Grade 3 -4). 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 27 of 83 
CONFIDENTIAL  Treatment -emergent abnormalities were dose-dependent and mostly mild to moderate in 
severity except for 4 cases of neutropenia and leukopenia Grade 4, 3 cases of 
thrombocytopenia Grade 4, and 4 cases of lymphopenia Grade 4. At baseline all of these 
patients had Grade 1 to 2 hematological toxicities with the exception of 2 patients with 
lymph openia Grade 3. During Cycle 1, median time to anemia, thrombocytopenia, leukopenia, 
neutropenia, and lymphocytopenia nadir was 10, 14.5, 15, 15, and 13 days, respectively. 
Median time to recovery from nadir was 3.5 days for hemoglobin, 7 days for platelets, 7 days 
for white  blood cells, 6.5 days for neutrophils, and 7.5 days for lymphocytes. Some of the 
hematological abnormalities detected were also reported as adverse events ( AEs) related to 
study medication, in particular: thrombocytopenia (4 patients, 21.1%, Grade 4 in 3 cases), neutropenia (3 patients, 15.8% all Grade 4), anemia and leukopenia (2 patients each, 10.5%, 
Grade 3 in both cases).  
Treatment -emergent abnormalities of blood chemistry parameters were mostly of Grade ≤ 2 
severity. Grade 3 abnormalities included: 2 cases of hypoalbuminemia in patients with renal 
metastases and a Grade 1 or Grade 2 value at baseline; 2 cases of increase in alkaline 
phosphatase (ALP) in 2 patients who already had a Grade 2 value at baseline; 1 case of 
hyponatremia in  one patient with a borderline Grade 3 value (129 mmol/L); 1 case of increase 
in aspartate aminotransferase (AST ) and alanine aminotransferase ( ALT ), 1 case of increase in 
lipase and 1 case of hypophosphatemia in one patient each. Only 1 case of increase i n ALP 
Grade 4 was recorded in 1 patient, who had already presented with a Grade 3 value at baseline, likely tumor -related. Only ALT Grade 3 and AST Grade 3, recorded in 1 patient treated at 
12 mg/m
2, were judged drug related by the Investigator. 
Hematological toxicity was dose -limiting at doses of 48  mg/m2/day for 5  consecutive days 
every 3  weeks. At the 48 mg/m2/day dose level, serious adverse events (SAEs) of 
thrombocytopenia Grade 4 and leukopenia Grade 4 occurred in 1 subject and at 36  mg/m2/day, 
thrombocytopenia Grade 4 and neutropenia Grade 4 occurred in 1 subject. No other relevant toxicities were observed during the study. Recovery for both platelets and ANC (even without colony-stimulating factors support) was prompt, being generally achieved in 1 to 2 weeks.  
A summary of Drug -related Treatment -emergent AEs by dose level is provided in  
Table 6 -1 below. 
 
 
  
 
 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 28 of 83 
CONFIDENTIAL  Table 6-1: Drug -related Treatment -emergent AEs  
MS-1286937H PO,  
Days 1-5, q 3 weeks  Assigned Dose Level (mg/m2/day)  
Any Dose 
Level (N=19)  6 (N=3)  12 
(N=3)  24 
(N=6)  36 
(N=4)  48 (n=3)  
n % n % n % n % n % n % 
Preferred Term  CTC Grade    
Any Term  1–4 11 57.9 2 66.7 2 66.7 2 33.3 3 75.0 2 66.7 
3–4 7 36.8     1 33.3 1 16.7 3 75.0 2 66.7 
Thrombocytopenia  1–4 4 21.1         1 16.7 2 50.0 1 33.3 
3–4 3 15.8             2 50.0 1 33.3 
Hypokalemia  1–4 3 15.8 1 33.3 1 33.3         1 33.3 
Neutropenia  1–4 3 15.8             2 50.0 1 33.3 
3–4 3 15.8             2 50.0 1 33.3 
Anemia NOS  1–4 2 10.5             1 25.0 1 33.3 
3–4 2 10.5             1 25.0 1 33.3 
MS-1286937H PO, Days 1 -5  
q 3 weeks  Assigned Dose Level (mg/m2/day)  
Any Dose 
Level (N=19)  6 (N=3)  12 
(N=3)  24 
(N=6)  36 
(N=4)  48 (n=3)  
n % n % n % n % n % n % 
Preferred Term  CTC Grade   
Aspartate 
aminotransferase 
elevation  1–4 2 10.5 1 33.3 1 33.3             
3–4 1 5.3     1 33.3             
Hypocalcemia  1–4 2 10.5 1 33.3             1 33.3 
Hypophosphataemia  1–4 2 10.5     1 33.3 1 16.7         
3–4 1 5.3         1 16.7         
Leukopenia NOS  1–4 2 10.5             1 25.0 1 33.3 
3–4 2 10.5             1 25.0 1 33.3 
Nausea  1–4 2 10.5 1 33.3             1 33.3 
Alanine 
aminotransferase 
elevation  1–4 1 5.3     1 33.3             
3–4 1 5.3     1 33.3             
Cholecystitis NOS  1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
Constipation  1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
Hyponatremia  1–4 1 5.3 1 33.3                 
Hypoxia  1–4 1 5.3             1 25.0     
3–4 1 5.3             1 25.0     
Lymphocyte 
percentage elevation  1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
Pneumonia NOS  1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
White blood cell 
decrease 1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 29 of 83 
CONFIDENTIAL  White blood cell count 
elevation  1–4 1 5.3                 1 33.3 
3–4 1 5.3                 1 33.3 
Source: CSR PLKA -937-001 ( Appendix 19.5) 
Further details regarding the nonclinical and clinical studies of onvansertib are provided in the 
onvansertib Investigator’s Brochure (IB). In addition, the current cytarabine and decitabine package inserts provide a description of the AE s that can be expected with their administration 
(Appendix 19.4).  
6.2 Study and Dose Rationale 
There is an urgent unmet medical need of subjects who have relapsed after or not responded to 
therapy for AML. Based on the body of data with therapies targeting PLK, there appears to be 
potential clinical benefit for subjects with AML. The aim of this study is to explore treatment with onvansertib in combination with either low -dose cytarabine or decitabine in subjects with 
AML. The onvansertib starting dose will be 12  mg/m
2 based on results from the Phase 1 study 
PLKA -937-001. In that study, a dose of 12 mg/m2 p.o. daily for 5 days was evaluated during 
dose escalation, and was not associated with myelosuppression of any grade. 
6.3 Risks and Benefits for Subjects 
The current safety clinical profile of onvansertib in treated subjects indicates that hematological toxicity (thrombocytopenia and neutropenia) is the most relevant toxicity of treatment. Recovery from hematologic toxicity was prompt in all reported subject cases, 
occurring in 1 to 2 weeks from the onset, even without colony- stimulating factor support.  
Therefore, the toxicity of onvansertib appears to be manageable with conventional treatments. 
No other relevant toxicities were observed during the study 
Clinical data with a compound similar to onvansertib ( ie, volasertib) in combination therapy 
produced promising results for subjects with AML. Onvansertib has several advantages over volasertib, including oral bioavailability and a higher degree of potency and specificity for the 
PLK1 isozyme. In a Phase 1 clinical study, onvansertib demonstrated a safety profile that was 
manageable, with transient AEs that were related to the drug’s mechanism of action.  
 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 30 of 83 
CONFIDENTIAL  7 STUDY OBJECTIVES  
7.1 Primary Objectives 
Phase 1 b: 
• To evaluate the DLTs and MTD, or Recommended Phase 2 Dose (RP2D), of 
onvansertib ( PCM -075) in combination w ith either low -dose cytarabine or decitabine in 
subjects with AML  
Phase 2 : 
• To assess the safety and tolerability of the combination of onvansertib ( PCM -075) at the 
MTD (or RP2D) and low-dose cytarabine, or the combination of onvansertib ( PCM -075) 
at the MTD  (or RP2D) and decitabine in  subjects with AML  
 
• To evaluate the preliminary anti -leukemic activity of the combination of onvansertib 
(PCM -075) at the MTD ( or RP2D)  and low-dose cytarabine, or the combination of 
onvansertib ( PCM -075) at the MTD  (or RP2D) and decitabine in subjects with AML 
7.2 Secondary Objectives 
Phase 1b: 
• To assess the incidence and severity of AEs according to National Cancer Institute 
Common Terminology Criteria  for Adverse Events (NCI -CTCAE , version 4.03) of 
onvansertib ( PCM -075) in combination with either low- dose cytarabine or decitabine in 
subjects with AML  
 
• To analyze the PK of onvansertib ( PCM -075) when given in combination with either 
low-dose cytarabine or decitabine in subjects with AML  
Phase 2:  
• To assess the incidence an d severity of AEs according to the NCI -CTCAE version 4.03 
of onvansertib ( PCM -075) in combination with either low -dose cytarabine or decitabine 
in subjects with AML  
 
• To analyze the PK of onvansertib ( PCM -075) when given in combination with either 
low-dose cytarabine or decitabine in subjects with AML  
7.3 Exploratory Objectives 
Phase 1b and Phase 2: 
• To explore additional analyses evaluating potential pharmacodynamic (PD) and 
diagnostic biomarkers of onvansertib (PCM-075) in subjects with AML    
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 31 of 83 
CONFIDENTIAL  8 INVESTIGATIONAL PL AN 
8.1 Overall Study Design and Plan 
This is a Phase 1b/2, open- label study of the safety and anti -leukemic activity of onvansertib  in 
combination with either low -dose cytarabine or decitabine in subjects with AML.  
In Phase 1b, subjects will have relapsed or refractory disease and must have received no more 
than 3 prior regimens for the treatment of their AML. Subjects may be treatme nt naïve as long 
as they are not candidates for or have refused intensive induction therapy. 
In Phase 2, subjects must have received no more than one prior regimen for the treatment of 
their AML. Subjects may be treatment naïve as long as they are not candidates for or have refused intensive induction therapy.   
In both phases, prior treatment with either low-dose cytarabine or decitabine for 
myelodysplastic syndromes (MDS) will not be considered a prior regimen. For subjects who 
have undergone hematopoieti c stem cell transplantation, the preparative (conditioning) 
regimen and transplant will be considered to be a single line of prior therapy. 
8.1.1 Phase 1b 
Phase 1b will be conducted in 2 arms of subjects allocated to receive either a combination of 
onvansertib and low-dose cytarabine, or a combination of onvansertib and decitabine.  
8.1.1.1 Combination Treatment Arms  
In Arm A, onvansertib will be administered p.o. Day 1 through Day 5 every 21 to 28 days in 
combination with cytarabine which will be administered in all coho rts as 20  mg/m
2 
subcutaneously (SC) once daily on Day 1 through Day 10 every 28 days. The starting dose of 
onvansertib in combination with cytarabine, will be 12 mg/m2 p.o. daily for 5 days (Dose Level 
0). On days where both agents are administered ( Days 1 -5), cytarabine will be administered 
first followed by onvansertib. Investigator assessment of subjects may allow them, at their 
discretion, to treat more frequently  than every 28 days; however, in no case may a cycle length 
be less than 21 days. 
In Arm B, onvansertib will be administered orally (p.o.) Day 1 through Day 5 every 21 to 28 
days in combination with decitabine, which will be administered consistently in all cohorts as 
20 mg/m2 IV over 1 hour on Day 1 through Day 5 every 28 da ys. Onvansertib administration, 
in combination with decitabine, will be initiated at a starting dose of 12  mg/m2 (Dose Level 0).  
The daily dose of decitabine will be administered first followed by onvansertib. Investigator assessment of subjects may allow them, at their discretion, to treat more frequently than every 
28 days; however, in no case may a cycle length be less than 21 days. 
The first 3 subjects will be allocated to Arm A (Cohort A1). If Cohort A1 is expanded to 6 
subjects prior to the first subject being enrolled in Arm B, then enrollment in Cohort A1 will be 
completed before enrollment begins in Arm B.  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 32 of 83 
CONFIDENTIAL  After all subjects are enrolled in Cohorts A1 and B1, subjects will enroll in subsequent cohorts 
based on the following decision rules:  
• If Arm A is open for enrollment, subjects will enroll in the open Arm A cohort regardless 
of dose level 
• If Arm A is closed to enrollment, subjects will enroll in the open Arm B cohort regardless 
of dose level 
8.1.1.2 Dose Escalation 
Dosing in each arm will proceed independently. Each arm will follow a standard 3+3 dose-escalation design in which the onvansertib dose will be escalated by 50% increments in 
successive cohorts of 3 subjects ( Table 8-1). If none of the 3 subjects enrolled at any dose level 
experience a DLT, the dose of onvansertib will be escalated by 1 dose level in each successive 
cohort. If 1 subject in the first 3 experiences a DLT, up to 3 additional subjects will be enrolled 
at that dose level. If there are no additional DLTs ( ie, ≤1 of 6 subjects with DLT), then dose 
escalation will again proceed. If there are 2 subjects who experience DLTs among the first 
3 subjects enrolled, or there is a second DLT in up to 6 subjects enrolled at any dose level, the 
MTD will be judged to have been exceeded and no additional subjects will be started at that dose. The MTD will then be established at a prior dose level or an additional cohort may be 
enrolled at an intermediate dose level upon agreement with the Sponsor, Medical Monitor, and 
Principal Investigator.  
The RP2D can be determined based on the assessment of safety, PK, PD, and preliminary 
efficacy of subjects treated at a dose level that has been cleared for safety , regardless of 
whether or not an MTD has been reached.  In this case, no further dose escalation will be done 
to determine a n MTD.  
Each cohort will be evaluated for toxicity, recovery of blood counts, and PK. DLTs w ill be 
evaluated for the first 28  days after initiation of therapy. In the case of pancytopenia present at 
Day 28 in the absence of other toxicity that constitutes a DLT, the duration for DLT evaluation 
will be extended to 42 days (unless the pancytopenia resolves between Day s 28 and 42, or is 
determined to be due to persistent leukemic involvement of the bone marrow or another cause 
unrelated to study therapy). Pancytopenia in the absence of another cause unrelated to study 
therapy that persists beyond Day  42 will be considered a DLT. If an I nvestigator elects to 
re-treat a subject prior to 28 days (allowed no sooner than on Day  22), the DLT evaluation 
period will end at the time of initiation of the second cycle therapy. Dose modifications and delays fo r safety will be performed as described in the protocol. After the first cycle, additional 
cycles can be administered to individual subjects based on I nvestigat or judg ment  if 
hematopoietic recovery is documented, and may incorporate delays or supportive ca re until 
hematopoietic function returns to baseline or Grade ≤1, as long as the subject is receiving 
clinical benefit without safety or tolerability issues . In the case that failure to achieve 
hematopoietic recovery is judged to be related to persistent leukemic involvement in the bone 
marrow, Investigators may re -initiate therapy according to their clinical judg ment  upon 
discussion with the Medical Monitor.  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 33 of 83 
CONFIDENTIAL  Investigators will also have the option for intra- subject dose escalation in later cycles if safety  
and tolerability have been demonstrated at higher doses of onvansertib. 
At any time during Phase  1b, the Sponsor, in consultation with the Safety Review Committee 
(SRC), may elect to discontinue enrollment into either arm of the study based on safety, 
efficacy , PK, and PD considerations. In this case, enrollment in the other arm will continue as 
described.  
Table 8-1: Onvansertib ( PCM -075) Dose and Dosing Levels 
Dose Level  Dose*  
-1 6 mg/m2 
0 (Initial dose)  12 mg/m2 
+1 18 mg/m2 
+2 27 mg/m2 
+3 40 mg/m2 
+4 60 mg/m2 
+5 90 mg/m2 
+6  135 mg/m2 
*Initial starting dose is Dose Level 0. If there are >1 DLTs at a dose level and the prior dose level was 
associated with 1 or fewer DLTs, an additional cohort may be enrolled at an intermediate dose level 
upon agreement with the Sponsor, Medical Monitor, and Principal Investigator.  
8.1.1.3 Preliminary Safety and Efficacy Assessment  
Following assessment of safety and preliminary efficacy in the first 5 dose level escalation 
cohorts (0: 12 mg/m2; +1: 18 mg/m2; +2: 27 mg/m2; +3: 40 mg/m2; +4: 60 mg/m2) in both 
Arm A (onvansertib plus low-dose cytarabine)  and Arm B  (onvansertib plus decitabine), the 
decision was made to discontinue Arm A from further dose escalation and subject enrollment.  
Arm B will continue forward with dose escalation as outlined in the protocol or until such time 
as the RP2D is determined at a dose level previously cleared for safety .  
The RP2D can  be determined based on the assessment of safety, PK, PD , and preliminary 
efficacy of subjects treated at a dose level that has been cleared for safety . In this case, no 
further dose escalation will be d one to determine an MTD. 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 34 of 83 
CONFIDENTIAL  8.1.2 Phase 2  
In Phase 2, a total of 32 subjects  will be enrolled at the RP2D to further evaluate safety  and 
preliminary efficacy. Onvansertib  will be administered p.o. on Day 1 through Day 5 every 
21 to 28 days, in combination with decitabine, administered consistently as 20  mg/m2 IV over 
1 hour on Day 1 through Day 5 every 28 days, with treatment modifications or delays based on 
return of hema topoietic function to baseline or Grade ≤1 toxicity for optimal subject 
management . The daily dose of decitabine will be administered first followed by onvansertib. 
Investigator assessment of subjects may allow them, at their discretion, to treat more frequently  
than every 28 days; however, in no case may a cycle length be less than 21 days. 
Subjects may continue treatment in the study at any dose until clinically significant diseas e 
progression or death, unacceptable toxicity, withdrawal of consent, or discontinuation based on 
Investigator discretion. Subjects will be followed for survival for up to 1 year after enrollment. 
AEs and concomitant medication use will be queried, monitored, and  recorded throughout the 
study. Safety evaluations will include: phys ical examinations, performance status, vital signs, 
electrocardiograms (ECGs), hematology and serum chemistry laboratory tests, and urinalysis.  
8.1.3 Study Endpoints  
Primary safety endpoints:  
1. Characterization of DLTs; characterization of AEs by type, incidence,  severity (graded 
by NCI -CTCAE version 4.03), seriousness, and relationship to treatment; effects on 
vital signs and laboratory parameters; and changes from baseline in ECGs, physical 
examinations, weight, and ECOG performance 
 
Primary efficacy endpoint:  
1. Rate of complete response (CR + CRi) in Phase 2, defined as a morphologic leukemia-free state (MLF; defined below) plus:  
For CR:  
a.       Subject is independent of transfusions  
b.       Absolute neutrophil count (ANC) of >1000/mm
3 
c.       Platelets of ≥1 00,000/mm3 
For CRi:  
a.      Meets all criteria for CR except for either neutropenia (ANC <1000/mm3) or     
thrombocytopenia (<100,000/mm3) but must include transfusion independence  
 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 35 of 83 
CONFIDENTIAL  Secondary endpoints: 
1.   Rate of achievement of a MLF in Phase 2, defined as:  
a.      Bone marrow (BM) <5% blasts in an aspirate with spicules (a BM biopsy 
should be performed if spicules are absent) 
b.      No blasts with Auer rods or persistence of extramedullary disease 
2.   Rate of partial response (PR) in Phase 2: A ll of the hematologic values for a CR but 
with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone 
marrow aspirate and a normalization of blood counts as noted above 
3.   Duration of response (DOR) in Phase 2: Time from documentation of response until 
documentation of recurrence of or progression of disease 
4.   Event-free survival (EFS) in Phase 2: Time from enrollment until disease progression 
or death from any cause  
5.   Overall survival (OS) in Phase 2: Time from enrollment u ntil death from any cause  
6.   Concentrations of onvansertib in plasma samples collected at pre- specified time points 
before and after administration of onvansertib, including maximum plasma concentration (C
max), trough plasma concentration (C min), time to  maximum plasma 
concentration (T max), area under the plasma concentration versus time curve (AUC), 
and plasma terminal elimination half -life (t 1/2) 
Exploratory endpoints: 
1. Blood samples for PD  and diagnostic biomarker evaluation 
2. Rate of complete response (C R+CRi), MLF, PR, DOR, EFS and OS in all enrolled 
subjects (Phases 1b and 2) 
8.2 Study Duration 
The screening period will be up to 28 days prior to enrollment. Onvansertib administration in 
both phases can continue for as long as the subject has documented hema topoietic recovery 
and for as long as the Investigator considers that the subject is receiving clinical benefit without safety or tolerability issues. In addition, subjects may be escalated or de -escalated to 
doses or schedules that are considered safe and  well tolerated, and in the best interest of the 
subject. Subjects will be followed for survival for up to 1 year after enrollment. 
8.3 Eligibility Criteria 
Subjects who meet all of the following inclusion criteria and none of the exclusion criteria will be el igible to be enrolled in the study.  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 36 of 83 
CONFIDENTIAL  8.3.1 Inclusion Criteria  
1. Disease Status and Prior Therapy : 
a. Histologically confirmed diagnosis of AML  
b. Phase 1b:  
i. Subjects with relapsed or refractory AML who have received no more 
than 3 prior treatment regimens for AML. Subjects who have received prior treatment with cytarabine or decitabine are not excluded. Prior treatment with either low -dose cytarabine or decitabine given for MDS 
will not be considered a prior regimen. For subjects who have undergone hematopoietic ste m cell transplantation, the preparative 
(conditioning) regimen and transplant will be considered to be a single line of prior therapy. 
OR 
ii. Subjects who are treatment naïve and are not candidates for or have 
refused intensive induction therapy. 
c. Phase 2:  
i. Subjects with relapsed or refractory AML who have received no more than 1 prior treatment regimen for AML.  Subjects who have received 
prior treatment with cytarabine or decitabine are not excluded. Prior treatment with either low -dose cytarabine or decitabine given for MDS 
will not be considered a prior regimen.   
OR 
ii. Subjects who are treatment naïve and are not candidates for or have 
refused intensive induction therapy.  
2. Age ≥18 years  
3. ECOG performance status ≤2 ( Appendix 19.3) 
4. Subjects must be willing and able to review, understand, and provide written consent 
before starting any study -specific procedures or  therapy.   
5. All men and women must agree to practice effective contraception during the entire study period and after discon tinuing study drug, unless documentation of infertility 
exists  
a. Sexually active, fertile women must use 2 effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from 
the time of informed consent and until at least 6 months after discontinuing study 
drug 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 37 of 83 
CONFIDENTIAL  b. Sexually active men and their sexual partners must use effective contraceptive 
methods from the time of subject informed consent and until at least 3 months 
after discontinuing study drug 
8.3.2 Exclusion Criteria  
Subjects must not meet any of the following exclusion criteria:  
1. Treatment -related AML or acute p romyelocytic leukemia (APL)  
2. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death  
3. Clinical evidence of active central nervous system leukemia at the time of screening  
4. ALT and/or AST ≥2.5 x upper limi t of normal (ULN)  
5. Total bilirubin >2.0 mg/dL (or >3.0  mg/dL in subjects with documented Gilbert 
syndrome) 
6. Serum creatinine ≥2.0 mg/dL  
7. NYHA Class III or IV heart disease ( Appendix 19.2), active ischemia or any other 
uncontrolled cardiac condition, or hypertensive or metabolic condition 
8. Myocardial infarction in the previous 12 weeks (from the start of treatment)  
9. Resting left ventricular ejection fraction <50% at the time of sc reening  
10. QT interval with Fridericia’s correction [QTcF] [ 16] >450 milliseconds for men, or 
>470 milliseconds for women. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of potentially correctible causes of QT prolongation ( eg, medications, hypokalemia), the triplicate ECG may be repeated once 
during screening and that result may be used to determine eligibility. 
11. Pregnant or breast feeding  
12. Active and uncontrolled disease (other than AML) or infection as judged by the treating physician  
13. Treatment with systemic therapy for the primary disease within 14 days of first dose (except for hydroxyurea or isolated doses of cytarabine or decitabine for WBC control) 
14. Grade 2 or greater toxicities from prior therapy, except for Grade 2 toxicities that are 
not expected to resolve and that in the judgment of the Investigator do not pose a significant safety risk to subject participation.  
15. Subjects with any o ther medical condition, including mental illness or substance abuse, 
deemed by the Investigator to be likely to interfere with the subject’s ability to sign the 
informed consent form ( ICF) or his/her ability to cooperate and participate in the study, 
or to interfere with the interpretation of the results  
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 38 of 83 
CONFIDENTIAL  8.3.3 Removal of Subjects from Therapy or Assessment  
Subjects will be discontinued from further study drug administration in the event of any of the 
following: 
• Intolerable toxicity as determined by the Investigat or 
• Progression of disease requiring an alternate therapy, in the opinion of Investigator 
• Entry into another therapeutic clinical study or start of additional anticancer therapy  
• Significant deviation from the protocol or eligibility criteria, in the opinion  of the 
Medical Monitor or Investigator  
• Noncompliance with study or follow-up procedures 
• Pregnancy  
• Subject withdrawal of consent and decision to discontinue participation 
• Termination of the study by the Sponsor 
• Any other reason that, in the opinion of the Investigator, would justify removal of the subject from the study. 
In the event that a subject is withdrawn from the study every effort will be made by the 
Investigator to document and report the reasons for withdrawal as thoroughly as possible. The 
reason (s) for withdrawal must be clearly reported on the appropriate page of the subject’s 
electronic case report form (eCRF). An eCRF must be completed for any subject who receives 
study drug. An End-of- Treatment reason must be recorded for any subject who receives study 
drug. The requirement for subject replacement is outlined in Section 11. 
If a subject is discontinued from the study for any reason, every effort must be made to 
perform all end of study ( EOS ) assessments ( Section 9.1). In the event that the subject fails to 
return for the necessary visit(s), an effort must be made to contact the subject to determine the 
reason, and this information should be recorded in the appropriate source record and reported as a deviation.  
8.4 STUDY DRUG TREATMENT  
8.4.1 Description of Study Treatments  
8.4.1.1 Onvanserti b (PCM -075) 
The chemical name of onvansertib is 1 -(2-hydroxyethyl) -8-{[5- (4-methylpiperazin -1-yl)-2-
(trifluoromethoxy) phenyl] amino}- 4,5- dihydro -1H-pyrazolo[4,3-h] quinazoline-3-
carboxamide fumarate salt.  
Onvansertib will be supplied as 5 mg and 20 mg (as free base) hard gelatin capsules that will 
be administered p.o. 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 39 of 83 
CONFIDENTIAL  • A Size 4 opaque caramel body and Swedish orange cap hard gelatin capsule contains 
6.09 mg of  onvansertib corresponding to 5 mg as free base, lactose monohydrate, 
pregelatinized starch , and  glyceryl behenate. The capsule body shell contains gelatin, 
black iron oxide, red iron oxide, yellow iron oxide, and titanium dioxide; the capsule cap shell contains gelatin, red iron oxide, and titanium dioxide.  
• A Size 4 opaque Swedish orange body and cap hard gelatin capsule contains 24.36 mg of onvansertib corresponding to 20 mg as free base, lactose monohydrate, pregelatinized starch , and  glyceryl behenate. The capsule shell contains gelatin, red iron 
oxide, and titanium dioxide.  
8.4.1.1.1 Storage Conditions 
Onvansertib is to be stored under refrigerated conditions (5°C ± 3°C; 36°F to 46°F) in the 
original packaging. 
8.4.1.1.2 Shelf -life 
When onvansertib is stored at 5°C±3°C (36°F to 46°F), on the basis of the available stability 
information, a shelf-life of 48 months is currently assigned to the 5 mg and 20 mg (as free base) hard gelatin capsules.  
Concurrent stability studies on the clinical batches are being conducted with 5 mg and 20 mg (as free base) hard gelatin capsules in order to evaluate the chemical, physical, and  
microbiological parameters. The onvansertib expiry date will be extended accordingly with the stability results. Any unexpected findings will be promptly communicated to study Investigators and to the applicable regulatory authorities.  
8.4.1.1.3 Dose Levels  
The Phase 1b onvansertib starting dose is 12 mg/m
2 (Dose Level 0). The dose of onvansertib 
will be escalated in sequential dose cohorts as described ( Section  8.1.1). Subjects will be 
assigned to a given dose regimen by the Principal Investigator based on prior dose levels tested 
and cohorts available. A subject will not be enrolled in the study until they complete all 
Screening evaluations, all eligibility criteria are met based on screening evaluations, and the eligibility criteria continues to be met following all baseline assessments on Day 1 of Cycle 1. 
Onvansertib will be administered p.o. on Day 1 through Day 5 every 21 to 28 days. 
Investigator assessment of subjects may allow them, at their discretion, to treat more frequently than every 28 days; however, in no case may a cycle length be less than 21 days. 
Note that additional dosing regimens and doses may be explored if, after review of the safety, 
PK/PD , and efficacy data for the Phase 1b  and Phase 2, alternative dosing schedules  and doses 
are deemed  to be in the best interest of understanding the safety and efficacy of the drug, and 
agreed upon by the Sponsor, Medical Monitor, and Principal Investigator.
 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 40 of 83 
CONFIDENTIAL  8.4.1.1.4 Dose Delays  
Subjects who experience any AE considered related to the study drug ( ie, adverse reaction or 
suspected adverse reaction per criteria in Section 10.1) will have their next dose of onvansertib 
held until all study drug -related toxicities have reverted to Grade 1 or to Baseline. All AEs 
must be attributed to study drugs unless there is a rea sonably acceptable alternate cause for the 
AEs.  
8.4.1.1.5 Dose Reduction 
Subjects who experience AEs of Grade ≥3 that is considered related to the study drug (ie, adverse reaction or suspected adverse reaction per criteria in Section 10.1) that do not show 
resolution with standard medical intervention by 7 days will have their next dose of 
onvansertib and all subsequent doses reduced by 1 dose level. If a second study drug- related 
toxicity such as this is encountered, the subject’s next dose will be further reduced by 1 dose 
level, t o an intermediate dose level, or subject may be discontinued from the study, based on 
the Investigator’s discretion. All AEs must b e attributed to study drugs unless there is a 
reasonably acceptable alternate cause for the AEs.  
8.4.1.2 Cytarabine 
The cytarabine dose will be 20 mg/m
2 SC daily on Day 1 through Day 10 every 28 days in 
Phase 1b. The dose of cytarabine will not be modified. On days where both agents are 
administered ( Days 1 -5), cytarabine will be administered first followed by onvansertib. 
Investigator assessment of subjects may allow them, at their discretion, to treat more frequently 
than every 28 days; however, in no case may a cycle length be less than 21 days. 
Storage of cytarabine should be in accordance with the product package insert 
(Appendix 19.4).  
8.4.1.3 Decitabine  
The decitabine dose will be 20 mg/m2 IV over 1 hour on Day 1 through Day 5 every 28 days in 
Phase 1b and Phase 2. The dose of decitabine will not be modified. The daily dose of 
decitabine will be administered first followed by onvansertib. Investigator assessm ent of 
subjects may allow them, at their discretion, to treat more frequently than every 28 days; 
however, in no case may a cycle length be less than 2 1 days. 
Storage of decitabine should be in accordance with the product package insert (Appendix 19.4).  
8.4.2 Dosing Schedule  
Subjects will receive study drugs according to the dosing schedule outlined in t ables in Section 
9.1. 
After review of the safety, PK, PD, and efficacy data from the Phase 1b portion of the study, 
and during the Phase 2 portion of the study, additional dosing schedules  and doses (eg, fewer 
TROV -052 
Clinic
al Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
Page 41 of 83 
CONFIDENTIAL  days with higher doses and shorter treatment cycles) in a given cohort may be explored if 
agreed upon by the Sponsor, Medical Monitor, an d Investigators, and are deemed to be 
important for the development of the study drug. 
8.4.3 Study D rug Inventory an d Accountability 
In acco rdance with cur rent Good Clinical P ractice ( GCP), each s tudy s ite will ke ep an 
accounting of all study drug supplies. Details of receipt, storage , administration, and return or 
destruc
tion will be recorded in the study drug accountability record according to the standard 
operating procedure of the study site. Copies of the study drug accountability record will be 
provided to the Sponsor. 
Study drug must only be dispensed to subjects enrolled in the study and only as directed b y this 
protocol
. Administration of study drugs will be accurately recorded in each subject’s source 
documents and case report form. 
8.4.4 Treatment C ompliance 
The study drug will be administered p.o. as 5 mg and 20 m g hard gelatin c apsules. C ompliance 
will be  ascertained b y Investigational Site s taff b y individual subject assessment and  
monitoring/accounting for return of 5 mg and 20 mg ha rd gelatin caps ules. 
8.4.5 Concomitant Med ications an d Treatments 
Concomitant medications  are all medications  (or treatmen ts) other than study drugs that are 
taken or  received b y the subject at any time dur ing the  study s tarting a t the time tha t the first 
dose of study drug was administered through the final study visit assessment. Use of all 
concomitant medications, including any change in therapy, must be recorded and updated in 
the source documentation and on the case report form. 
All inter -current medica l conditions  will be  treated a t the discretion  of the Investigator  
according to acceptable community and/or institutional standards  of medical care.  
Concomit
ant use of drugs with a know n high ris k of TdP should be avoided. F or a list of drugs 
known to increase the risk of TdP, please refer to the published list of drugs at 
www.crediblemeds.org. Specific exception is allowed for the use of ciprofloxacin, which is 
commonl
y used in patients with AML and carries a low risk of TdP. U nplanned use of drugs 
known to increase the risk of TdP or the QTc inter val should only occur during the conduct of 
the study with full consideration of the risks and benefits. Investigators should consult the TdP 
risk QT interval normogram included in Appendix 19.6. 
Prophylactic filgrastim, pegfilgrastim, or oprelvekin, or other drugs of this class will be 
allowed if clinically indicated; the subject may receive growt h factor support if needed and 
according t o American S ociety o f Clinical O ncology/American S ociety of  Hematology 
(ASC
O/ASH) guidelines. Erythropoietin, blood products, anti- emetics,  antimicrobials, and 
steroi
ds may be given at the discretion of the Investigator based on established criteria. 
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 42 of 83 
CONFIDENTIAL  No other anti- leukemia treatments are allowed in subjects while the subject is participating in 
this study.  
Subjects receiving warfarin or other coumarin -derivative anticoagulant should be monitored 
regularly for changes in prothrombin time or international normalized ratio (INR).   
 TROV -052 
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 07 Aug  2019 
 
Page 43 of 83 
CONFIDENTIAL  9 ASSESSMENTS  
9.1 Schedule of Assessments 
The schedule of events for Phase 1b Cycle 1, Phase 1b Cycle 2 and higher, and Phase 2 are 
provided in Table 9 -1, Table 9 -2, and Table 9 -3, respectively.  
Every attempt should be made to have each subject attend each visit as scheduled. Per protocol blood collection time points for determination of PK parameters should be adhered to as closely as possible.  
 
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 44 of 83 
CONFIDENTIAL  Table 9-1: Schedule of Events: Phase 1b Cycle 1  
Event  Screening  Baseline  On Treatment  Follow -up/EOS  
≤28 days 
prior to 
enrollment  ≤14 days 
prior to 
enrollment  Days -2 
to 1 Days  
(1-2 wks  after 
Discontinuation)  
1 2 3 4 5 6 7 8 9 10 15k 22k, l 
Informed consent  X                           
Relapsed/refractory AML: 
confirmation of diagnosis and cytogenetic analysis and molecular characterization obtained at diagnosis  X                 
    
      
ECOG performance status  X   X                     X 
History and physical examination
a X   X                     X 
Triplicate ECGb   X   X       X    X         
Blood chemistryc   X X              X   X  X X 
CBC, including differential, and platelet count
d   X      X         X   X   X  X  X 
Urinalysis    X                         
Pregnancy teste   X X                       X 
Confirmation of all eligibility criteria    X                         
 
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 45 of 83 
CONFIDENTIAL  ECHO or MUGA scan    X                       X 
Bone marrow aspirate & 
peripheral blood for measuring status of disease and diagnostic biomarker evaluation
f     X              
    
X   
Blood samples for PK analysisg       X    X   X   X X   
Blood samples for pharmacodynamic and biomarker analysis
h  X  X    X   
X   
X X  
Onvansertib ( PCM- 075) 
administration        X X X X X             
Cytarabine administrationi       X X X X X X X X X X       
Decitabine administrationi    X X X X X         
AE recording       X X X X X X X X X X X X X 
Concomitant medication recording  X  X X X  X  X X X X X X X X X X X 
Survivalj                X 
Footnotes for Table 9- 1: 
Abbreviations: AE=adverse event; ALT=alanine aminotransferase; AML=acute myeloid leukemia; AST=aspartate aminotransferase; BUN=blood urea nitrogen; 
CBC=complete blood count; ECG=electrocardiogram; ECHO=echocardiogram; ECOG=Eastern Cooperative Oncology Group (performance score); EOS=end of 
study; LDH=lactate dehydrogenase; MUGA=multigated acquisition scan; PK=pharmacokinetics  
a Including height, weight, vital signs, and general physical exam  
b Triplicate ECGs should be collected at pre- dose and 3 hours (±15 minutes) after dosing of onvansertib ( PCM -075) on Days 1 and 5 and once on Day 8.   
c Sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus, BUN, creatinine, glucose, albumin , total protein, alkaline phosphatase, 
total bilirubin, AST, ALT, LDH, and uric acid  
d CBC, to include differential and platelet count should be repeated as clinically indicated  
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 46 of 83 
CONFIDENTIAL  e A serum or urine pregnancy test should be performed for women of childbearing potential at least once per cycle prior to dosing, as well as during 
Screening and at the Follow -up/EOS visit.  
f Bone marrow aspirate and peripheral blood (complete blood count, differential, and platelet count; flow cytometry is optional) should be performed 
within 15 days prior to the first dose of study drug to document disease . If clinically appropriate, a bone marrow aspirate (or biopsy if necessary) should 
be performed 14- 21 days after the start of therapy to document disease status . If hypoplasia is pre sent, then a repeat aspirate/biopsy at the time of 
hematologic recovery based on peripheral blood counts should be obtained to document remission. If hypoplasia is not document ed or is indeterminate, 
a repeat biopsy should be obtained, if clinically app ropriate, in another 7 -14 days to clarify the persistence of leukemia. If cytogenetics were initially 
abnormal, include cytogenetics as part of the remission documentation. For peripheral blood, include CBC, including different ial and platelet count.   
g Blood samples for PK analysis will be collected predose , and 0.5, 1, 2, 3, 4, 8 (all ±10 minutes ), and 24 hours (±1 hour) after administration of 
onvansertib on Days 1  and 5, as well as once each on Days  8, 15, and 22.  
h Blood samples for pharmacodynamic and diagnostic biomarker analysis will be obtained at screening in conjunction with the bone marrow aspirate; on Day 1 pre dose, 3 hours (±10 minutes)  and 24 hours  (±1 hour) after administration of onvansertib;  on Day 5 pre dose, 3 hours (±10 minutes) after 
administration of onvansertib in conjunction with the PK  sample being obtained at those time points, as well as once each on Days 8, 15, and 22.  
i Subjects will receive either cytarabine or decitabine based on the arm in which they are enrolled ( Section 8.1.1). On days where both agents are 
administered ( Days 1 -5), cytarabine will be administered first followed by onva nsertib . For patients receiving decitabine, the decitabine will be 
administered first followed by onvansertib . 
j After cessation of study treatment, subjects will be followed for survival every 2 months for 1 year  (may be by telephone). 
k Visits on Day s 15 and 22 may occur ±1 day for subject convenience.  
l Investigator assessment of subjects may allow them, at their discretion, to treat more frequently than every 28 days; however, in no case may a cycle length be less than 21 days.
 If an Investigator elects to  re-treat a subject prior to 28 days (allowed no sooner than on Day 22), the DLT evaluation period 
will end at the time of initiation of the second cycle therapy.   
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 47 of 83 
CONFIDENTIAL  Table 9-2: Schedule of Events: Phase 1b Cycle  ≥2 
Event  On Treatment  Follow -up/EOS  
Days  (1-2 wks after 
Discontinuation)  1 2 3 4 5 6 7 8 9 10 15k 22k, j, l 
ECOG performance status  X                   X 
History and physical examinationa X                   X 
Triplicate ECGb X       X             
Blood chemistryc X            X   X X X 
CBC, including differential, and platelet countd X       X     X    X X  X 
Urinalysisd X                     
Pregnancy teste X                     
ECHO or MUGA scan                      X 
Bone marrow aspirate & peripheral blood for 
measuring status of disease and diagnostic biomarker 
evaluationf        
   
X  
Blood samples for PK evaluationg X    X   X   X X  
Blood samples for pharmacodynamic and diagnostic 
biomarker evaluationh X       X   X   X X   
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 48 of 83 
CONFIDENTIAL  Event  On Treatment  Follow -up/EOS  
Days  (1-2 wks after 
Discontinuation)  1 2 3 4 5 6 7 8 9 10 15k 22k, j, l 
Onvansertib ( PCM -075) administration  X X X X X             
Cytarabine administrationi X X X X X X X X X X       
Decitabine administrationi X X X X X         
AE recording  X X X X X X X X X X X X X 
Concomitant medication recording   X X  X X X X X X X X X X X 
Survivalj             X 
Footnotes for Table 9- 2: 
Abbreviations: AE=adverse event; BUN=blood urea nitrogen;  ALT=  alanine aminotransferase; AST=  aspartate aminotransferase; CBC=complete blood count; 
ECG= electrocardiogram; ECHO=echocardiogram; ECOG=Eastern Cooperative Oncology Group (performance score);  EOS=end of study;  LDH=lactate 
dehydrogenase; MUGA=multigated acquisition scan; PK=pharmacokinetics; TBD=timing based on prior marrow and blood counts, as s pecified in ( f). 
a Physical examination should include weight, vital signs, and general physical exam.  
b Triplicate ECGs will also be collected pre -dose and 3 hours (±15 minutes) after dosing of onvansertib on Days 1 and 5 ( Cycle  2 only). ECGs are not 
required after Cycle  2. 
c Sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus, BUN, creatinine, glucose, albumin, total protein, a lkaline phosphatase, 
total bilirubin, AST, ALT, LDH, and uric acid . Day 1 chemistry values may be obtained up to 3 days prior. 
d CBC, to include differential and platelet count may be repeated as clinically indicated. A serum or urine pregnancy test shou ld be performed for women 
of childbearing potential at least once per cycle prior to dosing, as well as at the Follow -up/EOS visit.  Day 1 urinalysis and pregnancy tests may be 
obtained up to 3 days prior.  
e A serum or urine pregnancy test should be performed for women of childbearing potential at least once per cycle prior to dosi ng. 
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 49 of 83 
CONFIDENTIAL  f Bone marrow aspirate (and biopsy if necessary) should be obtained to document remission status prior to Cycle  3 and every other cycle therea fter, 
which may be obtained at any time within 10 days to cycle Day  1. If cytogenetics were initially abnormal, include cytogenetics as part of the remission 
documentation. For peripheral blood, include CBC, differential & platelet count.  
g Blood samples for PK evaluation of onvansertib should be collected  at Cycle 2 only , if feasible, on Days 1 and 5 at pre dose, 3 hours ( ±10 minutes ), and 
24 hours (±1 hour) after administration of onvansertib , as well as once each on Days 8, 15 , and 22.  
h Blood samples for pharmacodynamic and biomarker evaluation of onvansertib should be collected, if feasible, at Cycles 2 and 3 on Days 1 and 5 at pre -
dose and 3 hours ( ±10 minutes ) after administration of onvansertib, as well as once each on Days 8, 15, and 22. For Cycle 4 and beyond, blood samples 
should be collected pre -dose on Days 1 and 15.  
i Subjects will receive either cytarabine or decitabine based on the arm in which they are enrolled ( Section 8.1.1). On days where both agents are  
administered ( Days 1 -5), cytarabine will be administered first followed by onvansertib . For patients receiving decitabine, the decitabine will be 
administered first followed by onvansertib . 
j After cessation of study treatment, subjects will be followed for  survival every 2 months for 1 year  (may be by telephone). 
k Visits on Day s 15 and 22 may occur ±1 day for subject convenience.  
l Investigator assessment of subjects may allow them, at their discretion, to treat more frequently  than every 28 days; however, in no case may a cycle 
length be less than 21 days.  
 
  
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 50 of 83 
CONFIDENTIAL  Table 9-3: Schedule of Events: Phase 2 (all cycles)  
Event  Screening  Baseline  On Treatment  Follow -up/EOS  
≤28 days 
prior to 
enrollment  ≤14 days 
prior to 
enrollment  Days -2 to 
1 Days  
(1-2 wks after 
Discontinuation)  1 2 3 4 5 6 7 8 9 10 15k 22k, 
l 
Informed consent  X                           
Confirmation of AML and 
prior therapy, either 
relapsed/refractory or newly diagnosed, cytogenetic analysis , and  molecular 
characterization obtained at 
diagnosis  X                 
    
      
ECOG performance status  X   X                     X 
History and physical 
examinationa X   X                     X 
Triplicate ECGb   X  X       X   X         
Blood chemistryc   X X             X   X  X X 
CBC, including differential, 
and platelet countd   X  X        X    X    X X  X 
Urinalysise   X X                      
Pregnancy teste   X  X                       
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 51 of 83 
CONFIDENTIAL  Event  Screening  Baseline  On Treatment  Follow -up/EOS  
≤28 days 
prior to 
enrollment  ≤14 days 
prior to 
enrollment  Days -2 to 
1 Days  
(1-2 wks after 
Discontinuation)  1 2 3 4 5 6 7 8 9 10 15k 22k, 
l 
Confirmation of all eligibility 
criteria    X                         
ECHO or MUGA scan    X                       X 
Bone marrow aspirate & 
peripheral blood for measuring 
status of disease and diagnostic 
biomarker evaluationf    X                  X   
Blood samples for PK 
analysisg       X    X   X   X X   
Blood samples for 
pharmacodynamic and 
diagnostic biomarker 
evaluationh  X  X    X   X   X X  
Onvansertib ( PCM -075) 
administration        X X X X X             
Decitabine administrationi    X X X X X         
AE recording      X X X X X X X X X X X X X X 
Concomitant medication 
recording  X  X X X  X X X X X X X X X X X X 
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 52 of 83 
CONFIDENTIAL  Event  Screening  Baseline  On Treatment  Follow -up/EOS  
≤28 days 
prior to 
enrollment  ≤14 days 
prior to 
enrollment  Days -2 to 
1 Days  
(1-2 wks after 
Discontinuation)  1 2 3 4 5 6 7 8 9 10 15k 22k, 
l 
Survivalj                X 
Footnotes for Table 9- 3: 
Abbreviations: AE=adverse event; ALT=alanine aminotransferase; AML=acute myeloid leukemia; AST=aspartate aminotransferase; BUN =blood urea nitrogen; 
CBC=complete blood count; ECG=electrocardiogram; ECHO=echocardiogram; ECOG=Eastern Cooperative Oncology Group (performance score); EOS=end of 
study; LDH=lactate dehydrogenase; MUGA=multigated acquisition scan; PK=pharmacokinetics  
 
a Physical examination should include height (screening only), weight, vital signs, and general physical exam. History and phys ical should be repeated 
prior to each cycle of therapy.  
b Triplicate ECGs should also be collected at pre- dose and 3 hours after dosing on Day s 1 and 5 and on Day  8 during Cycle  1. Triplicate ECGs should 
also be collected at pre- dose and 3 hours after dosing on Day s 1 and 5 during Cycle  2 (Day 8 not required for Cycle  2). ECGs are not required after 
Cycle  2. 
c Sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus, BUN, creatinine, glucose, albumin, total protein, a lkaline phosphatase, 
total bilirubin, AST, ALT, LDH, and uric acid . Day 1 chemistry values may be obtained up to 3 days prior.  
d CBC, to inclu de differential and platelet count should be repeated as clinically indicated. 
e A serum or urine pregnancy test should be performed for women of childbearing potential at least once per cycle prior to  dosing, as well as at the 
Follow -up/EOS visit.  Day 1 urinalysis and pregnancy test may be obtained up to 3 days prior.  
f Bone marrow aspirate and peripheral blood (complete blood count, differential, and platelet count; flow cytometry is optional) should be  performed 
within 15 days prior to the first dose of study drug to document disease . If clinically appropriate, a bone marrow aspirate (or biopsy if necessary) should 
be performed 14 to 21 days after the start of therapy to document disease status . If hypoplasia is present, then a repeat aspirate/biopsy at the time of 
hematologic recovery based on peripheral blood counts should be obtained to document remission. If hypoplasia is not document ed or is indeterminate, 
a repeat biopsy should be obtained in c linically appropriate in another 7 -14 days to clarify the persistence of leukemia. If cytogenetics were initially 
abnormal, include cytogenetics as part of the remission documentation . Bone marrow aspirate (and biopsy if necessary) should also be obtained to 
document remission status prior to Cycle  3 and every other cycle thereafter, which may be obtained at any time within 10 days prior to Cycle  Day 1. If 
 
                                                                                                           TROV -052 
                                                                                        Clinical Study Protocol  
                                                                                  Amendment 2, Version 6.0  
Onvansertib (PCM -075)                                                                                               Date: 0 7 Aug 2019  
 
Page 53 of 83 
CONFIDENTIAL  cytogenetics were initially abnormal, include cytogenetics as part of the remission documentation. For  peripheral blood, include CBC, differential & 
platelet count.  
g Blood samples for PK  analysis will be collected at Cycle 1 at pre -dose, and 0.5, 1, 2, 3, 4, 8 (all ± 10 minutes ), and 24 hours ( ± 1 hour ) after 
administration of onvansertib on Days 1 and 5, as well as once each on Days 8, 15 , and 22. At  Cycle  2, blood samples should be collected, if feasible, 
pre-dose, 3 hours (± 10 minutes ) and 24 hours (± 1 hour) after administration of onvansertib on Days 1 and 5, and once each on Days 8, 15, and 22.  
h Blood samples for pharmacodynamic and diagnostic biomarker analysis will be obtained at screening in conjunction with the bone marrow aspirate; at 
Cycle 1: on Day 1 pre -dose, 3 hours (±10 minutes)  and 24 hours  (±1 hour) after administration of onvansertib;  on D ay 5 pre -dose, 3 hours (±10 minutes) 
after administration of onvansertib in conjunction with the PK  sample being obtained at those time points, as well as once each on Days 8, 15, and 22.  
At Cycles 2 and 3, blood samples should be collected, if feasible on  Days 1 and 5 at  pre-dose, 3 hours (± 10 minutes ) after administration of 
onvansertib, and once each on Days 8, 15, and 22. For Cycle 4 and beyond, blood samples should be collected, if feasible, on Days 1 (pre -dose) and 15. 
The schedule for obtaining these may be amended based on results of prior evaluations.  
i Decitabine will be administered first followed by onvansertib . 
j After  cessation of study treatment, subjects will be followed for survival every 2 months for 1 year (may be by telephone).  
k Visits on Day s 15 and 22 may occur ±1 day for subject convenience.   
l Investigator assessment of subjects may allow them, at their discretion, to treat more frequently  than every 28 days; however, in no case may a cycle 
length be less than 21 days.  
 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 54 of 83 
CONFIDENTIAL  9.2 Study Visits 
The following sections describe the pretreatment, treatment, and post- treatment evaluations in 
this study.  
9.2.1 Phase 1b 
9.2.1.1 Pretreatment Evaluations (Screening and Baseline)  
The Investigator is responsible for keeping a record of all subjects screened for entry into the 
study and those that are subsequently excluded. The reason(s) for subject exclusion from the study must also be recorded.  
Each subject (or subje ct’s legal rep resentative if applicable) must provide written informed 
consent before any study- specific assessments may be performed.  
The following screening procedures must be performed within 28 days prior to the first dose of 
study drug: 
1. Complete history of AML, to include date and confirmation of diagnosis; dates of prior 
therapies as well as date of documented recurrence/progression are required for Phase 1b only. Cytogenetic analysis and molecular characterization obtained at diagnosis will be recorded.  
2. Record ECO G performance status.  
3. Complete medical history to include pertinent medical conditions and a careful history of all prior medical treatments .  
4. Physical examination, including height (at screening only), weight, and vital signs .  
The following screening procedures must be performed within 14 days prior to the first dose of 
study drug: 
1. Perform triplicate ECG  
2. Blood sample collection for clinical chemistry laboratory testing  
3. Blood sample collection for hematology laboratory testing  
4. Blood sample collection for PD  and diagnostic biomarker evaluation 
5. Urine sample collection  
6. Pregnancy test for women of childbearing potential within 72 hours prior to first dose of 
study drug.  
7. Recording of concomitant medication use 
8. Perform an echocardiography ( ECHO) o r 
multigated acquisition (MUGA) scan  
9. Confirmation of all eligibility criteria  
10. Bone marrow aspirate and  peripheral blood sample  for measuring status of disease and 
performing biomarker analysis  
The following baseline procedures must be performed within 2 days prior to the first dose of 
study drug: 
1. Record ECOG performance status  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 55 of 83 
CONFIDENTIAL  2. Interval medical history to update pertinent medical conditions  
3. Physical examination, including weight and vital signs  
4. Blood sample collection for clinical chemistry laboratory testing  
5. Blood sample collection for hematology laboratory testing  
6. Recording of concomitant medication use 
9.2.1.2 Evaluations During Treatment 
Day 1 through Day 28 procedures: 
1. Study drug administration: 
a. Onvansertib on Day 1 through Day 5 
i. Cytarabine on Day 1 through Day 10, or 
ii. Decitabine on Day 1 through Day 5 
b. On days where both agents are administered (D ays 1 -5), cytarabine will be 
administered first followed by onvansertib. For  patients receiving decitabin e, the 
decitabine will be administered first followed by onvansertib. 
c. Investigator assessment of subjects may allow them, at their discretion, to treat 
more frequently  than every 28 days; however, in no case may a cycle length be 
less than 21 days. 
2. Triplicate ECGs will be collected at pre -dose and 3 hours (± 15 minutes) after dosing of 
onvansertib on Day s 1 and 5 ( Cycle s 1 and 2) and once on Day  8 (Cycle  1 only) 
3. Pregnancy testing for women of childbearing potential will be performed prior to each cycle of t herapy  
4. If clinically appropriate, a bone marrow aspirate (or biopsy if necessary) should be performed 14 to 21 days after the start of therapy to document disease status. If hypoplasia is present, then a repeat aspirate/biopsy at the time of hematologic re covery 
based on peripheral blood counts should be obtained to document remission. If hypoplasia is not documented or is indeterminate, a repeat biopsy should be obtained in clinically appropriate in another 7  to 14 days to clarify the persistence of leukem ia. If 
cytogenetics were initially abnormal, include cytogenetics as part of the remission documentation. For peripheral blood, include complete blood count ( CBC ), including 
differential and platelet count. A repeat bone marrow aspirate (or biopsy if neces sary) 
will be obtained prior to Cycle  3 and every other cycle thereafter or as clinically indicated  
5. Blood samples for PK  analysis will be collected on Day s 1 and 5 of the first  cycle  pre-
dose and at 0.5, 1, 2, 3, 4, 8, and 24 hours after administration of onvansertib. Blood samples for PD  and diagnostic biomarker evaluation of onvansertib will be collected on 
Day 1  of the first cycle at pre -dose, 3 hours, and 24 hours, and on Day 5 at pre -dose and 
3 hours after administration of onvansertib. Blood samples for PK , PD,  and diagnostic 
biomarker analysis will also be obtained for the first cycle weekly on Days 8, 15, and 22. For Cycle  2 (only), blood samples for PK analysis will be collected on Days 1 and 5 at 
pre-dose, 3 hours, and 24 hours post dose, and weekly on Days 8, 15, and 22. Blood 
samples for PD and diagnostic biomarker will be collected for Cycles 2 and 3 on Days 1 and 5 at pre-dose, 3 hours after administration of onvansertib, and weekly on Days 8, 15, 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 56 of 83 
CONFIDENTIAL  and 22; for Cycle 4 and beyond on Day 1 at pre-dose and Day 15. Visits on Day s 15 and 
22 may occur ±1 day for subject convenience. 
6. Blood sample collection for CBC, including differential and platelet count, and blood 
chemistry will be performed on D ays 1 and 5 and weekly after the start of the cycle 
(Days 8, 15, and 22) and as clinically indicated.   
7. Urine sample collection (once per cycle pre-dose) 
8. AE and concomitant medication recording daily during dosing and then weekly 
9.2.1.3 Post-Treatment Evaluations (Follow-up/End of Study) 
Within 14 days after decision to discontinue patient from further treatment, the following 
evaluations will be conducted:  
1. Record ECOG performance status 
2. Physical examination  
3. Pregnancy test for women of childbearing potential 
4. Blood sample collection for clinical chemistry laboratory testing  
5. Blood sample collection for hematology laboratory testing  
6. Perform ECHO or MUGA scan  
7. AE recording  
8. Recording of concomitant medication use 
Any subject with a suspected study drug -related toxicity at the last follow -up visit must be 
followed until resolution or until the event is considered irreversible. This may require additional clinical assessments and laboratory tests. The follow -up results will be recorded on the 
appropriate page of the case report form, as well as in the subject's source documentation. 
9.2.2 Phase 2  
9.2.2.1 Pretreatment Evaluations (Screening and Baseline)  
The Investigator is responsible for keeping a record of all subjects screened for entry into the study and those that are subsequently excluded. The reason(s) for subject exclusion from the study must also be recorded.  
Each subject (or subject’s legal representative if applicable) must provide written informed 
consent before any study- specific assessments may b e performed.  
The following screening procedures must be performed within 28 days prior to the first dose of study drug: 
1. Complete history of AML, to include date and confirmation of diagnosis and prior 
therapy, and cytogenetic analysis and molecular charact erization obtained at diagnosis 
2. Record ECOG performance status  
3. Complete medical history to include pertinent medical conditions and a careful history of all prior medical treatments  
4. Physical examination, including height (at screening only), weight, and vital signs  
5. Recording of concomitant medication use  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 57 of 83 
CONFIDENTIAL  The following screening procedures must be performed within 14 days prior to the first dose of 
study drug: 
1. Perform triplicate ECG  
2. Blood sample collection for clinical chemistry laboratory testing  
3. Blood sample collection for hematology laboratory testing  
4. Blood sample collection for PD and diagnostic biomarker evaluation 
5. Urine sample collection  
6. Pregnancy test fo r women of childbearing potential within 72 hours prior to first dose of 
study drug 
7. Confirmation of all eligibility criteria  
8. Record concomitant medication use 
9. Perform ECHO or MUGA scan  
10. Bone marrow aspirate and  peripheral blood sample for measuring status of disease and 
performing biomarker analysis  
The following baseline procedures must be performed within 2 days prior to the first dose of 
study drug: 
1. Record ECOG performance status  
2. Complete medical history to include pertinent medical conditions and a careful histo ry of 
all prior medical treatments  
3. Physical examination, including weight and vital signs  
4. Blood sample collection for clinical chemistry laboratory testing  
5. Blood sample collection for hematology laboratory testing  
6. Recording of concomitant medication use   
9.2.2.2 Evaluations During Treatment 
Day 1 through Day 28 procedures: 
1. Study drug administration: 
a. Onvansertib at the RP2D on Day 1 through Day 5 
i. Decitabine on Day 1 through Day 5 
b. On days where both agents are administered (D ays 1 -5), decitabine will be 
administere d first followed by onvansertib. 
c. Dosing of onvansertib may be delayed for safety if any hematologic toxicity 
and/or toxicity determined to be related to drug administration remains >Grade 2  
d. Investigator assessment of subjects may allow them, at their discr etion, to treat 
more frequently  than every 28 days; however, in no case may a cycle length be 
less than 21 days. 
2. Triplicate ECGs will be collected at pre -dose and 3 hours after dosing on Day s 1 and 5 
(Cycle s 1 and 2), and once on Day  8 (Cycle  1 only). ECGs are not required after Cycle  2 
3. Pregnancy testing for women of childbearing potential will be performed prior to each cycle of therapy  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 58 of 83 
CONFIDENTIAL  4. If clin ically appropriate, a bone marrow aspirate (or biopsy if necessary) should be 
performed 14 to 21 days after the st art of therapy to document disease status. If 
hypoplasia is present, then a repeat aspirate/biopsy at the time of hematologic recovery 
based on peripheral blood counts should be obtained to document remission. If hypoplasia is not documented or is indeterminate, a repeat biopsy should be obtained in clinically appropriate in another 7  to 14 days to clarify the persistence of leukemia. If 
cytogenetics were initially abnormal, include cytogenetics as part of the remission documentation. For peripheral blood, include CBC, including differential and platelet count. A repeat bone marrow aspirate (or biopsy if necessary) will be obtained prior to Cycle  3 and every other cycle thereafter or as clinically indicated  
5. Blood samples for PK  analysis will be collected on Day s 1 and 5 of the first cycle pre -
dose and at 0.5, 1, 2, 3, 4, 8, and 24 hours after administration of onvansertib. Blood samples for PD  and diagnostic biomarker evaluation of onvansertib will be collected on 
Day 1 of the first cycle at pre -dose, 3 hours, and 24 hours and on Day 5 at pre-dose, 
3 hours after administration of onvansertib. Blood samples for PK , PD and diagnostic 
biomarker analysis will also be obtained for the first cycle wee kly on Days 8, 15, and 22. 
For Cycle  2 (only), blood samples for PK analysis will be collected on Day 1 and Day 5 
at pre-dose, 3 hours and 24 hours post dose and weekly on Days 8, 15, and 22. Blood 
samples for PD and diagnostic biomarker will be collected for Cycles 2 and 3 on Day 1 and 5 at pre-dose, 3 hours after administration of onvansertib and weekly on Days 8, 15, 
22; for Cycles 4 and beyond on Day 1 at pre-dose and Day 15. Visits on Day s 15 and 22 
may occur ±1 day for subject convenience.  
6. Blood sample collection for CBC, including differential and platelet count, and blood chemistry will be performed on Day 5 and weekly after the start of the cycle (Days 8, 15, and 22) and as clinically indicated. 
7. Urine sample collection (once per cycle, pr e-dose) 
8. AE and concomitant medication recording daily during dosing and then weekly 
9.2.2.3 Post-treatment Evaluations (Follow -up/End of Study) 
Within 14 days after the decision to discontinue the patient from further treatment, the following 
evaluations will be c onducted:  
1. Record ECOG performance status 
2. Physical examination  
3. Pregnancy test for women of childbearing potential 
4. Blood sample collection for clinical chemistry laboratory testing  
5. Blood sample collection for hematology laboratory testing  
6. Perform ECHO or M UGA scan  
7. AE recording  
8. Recording of concomitant medication use 
Any subject with a suspected study drug- related toxicity at the last follow -up visit must be 
followed until resolution or until the event is considered irreversible. This may require additional 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 59 of 83 
CONFIDENTIAL  clinical assessments and laboratory tests. The follow -up results will be recorded on the 
appropriate page of the CRF, as well as in the subject's source documentation. 
After completion of treatment, subjects will be followed every 2 months for survival for 1 year . 
Survival follow-up may be obtained by telephone. 
9.3 Efficacy Assessments 
All subjects evaluable for anti -leukemic activity will be assessed for response to treatment using 
the recommendations of the International Working Group (IWG) for standardization of response 
criteria, treatment outcomes, and reporting for therapeutic studies. [ 17]  
9.3.1 Efficacy Variables  
Response criteria will be based on the International Working Group for AML.  [17] The primar y 
efficacy variable is leukemia responses, evaluated by the Investigator based on bone marrow 
aspirate and peripheral blood examination. 
Efficacy endpoints are per NCCN.  [18] Responders are subjects who obtain a complete response 
(CR), CR with incomplete blood count recovery (CRi), or partial response (PR), with or without cytogenetic response, hematologic improvements (HI), and morphologic leukemia- free (MLF) 
state. Other criteria include DOR, EFS, and OS. Briefly, criter ia are defined as follows:
 
9.3.1.1 Morphologic Leukemia- free State  
• Bone marrow <5% blasts in an aspirate with spicules (a BM biopsy should be performed 
if spicules are absent)  
• No blasts with Auer rods or persistence of extramedullary disease  
9.3.1.2 Complete Response 
Complete response is defined by the following criteria: 
• Morphologic leukemia- free state plus:  
- Subject is independent of transfusions  
- Absolute neutrophil count of >1000/mm3 
- Platelets of ≥100,000/mm3 
9.3.1.3 Complete Response with Incomplete Blood Count Re covery  
• Complete response with incomplete blood count recovery meets all criteria for CR 
except for either neutropenia (ANC <1000/mm3) or thrombocytopenia (<100,000/mm3) 
but must include transfusion independence 
9.3.1.4 Partial Response 
• All of the hematologic value s for a CR but with a decrease of at least 50% in the 
percentage of blasts to 5% to 25% in the bone marrow aspirate and a normalization of 
blood counts as noted above. 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 60 of 83 
CONFIDENTIAL  9.3.1.5 Duration of Response  
• Time from documentation of response until documentation of recurre nce of or 
progression of disease. 
9.3.1.6 Event -free Survival  
• Time from enrollment until disease progression or death from any cause 
9.3.1.7 Overall Survival  
• Time from enrollment until death from any cause.  
9.4 Safety Assessments 
Toxicity will be graded using the National Cancer Institute Common Terminology Criteria 
(NCI -CTCAE version 4.03).  
• Safety analysis will be conducted on all subjects who have received at least one dose of study drug, and will include the frequency of all AEs and laboratory abnormalities as well as 
the frequency of dose interruptions, dose reductions, and treatment discontinuation. 
• In Phase 1b, DLTs will be considered to be any non- hematologic Grade 3 abnormalities that 
persist >7 days without decreasing in severity despite standards of care, are clinic ally 
significant, or that are Grade 4 and symptomatic . Exceptions and additional parameters for 
assessment of non-hematologic DLTs are provided in the protocol. For hematologic toxicities, only persistent pancytopenia resistant to current standards of care that continues 
for ≥42 days and is not related to leukemic infiltration or another cause unrelated to study therapy will be considered as a DLT, since marrow aplasia is an expected consequence of 
AML therapy.  
• Any subject that has not completed a full initial cycle and received at least 80% of study 
drug due to issues other than DLTs, including disease progression, will be replaced. 
Additional safety assessments will include physical examination; medical history; ECG; ECOG 
performance status; weight; vital signs measurements; clinical laboratory testing (hematology, 
clinical chemistry, and urinalysis) and MUGA or ECHO scans. 
Safety assessments will be performed as per the Schedule of Assessments ( Section 9.1). Safety 
assessment may be performed at additional time points during the study at the discretion of the 
Investigator in the interest of subject safety.  
The SRC, consisting of the Principal Investigators and Medical Monitor, will monitor subjects 
for safety and to evaluate efficacy of onvansertib doses to minimize exposure of subjects to a 
non-efficacious dose level.  
9.5 Pharmacokinetic Assessments  
Pharmacokinetic analysis will be obtaine d as outlined in Section 9.2.1 and Section 9.2.2. 
Pharmacokinetic parameters to be determined will include: 
• Maximum concentration (C max) 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 61 of 83 
CONFIDENTIAL  • Time of maximum concentration (T max) 
• Area under the curve over the first 24 hours (AUC 0-24) 
• Drug elimination half -life (t 1∕2) 
9.6 Pharmacodynamic and Biomarker Evaluation 
Pharmacodynamic and biomarker evaluation will be obtained as outlined in Section 9.2.1 and 
Section 9.2.2. Details of the PD  and biomarker evaluations will be included in the laboratory 
manual.  
10 ADVERSE EVENT REPORT ING  
10.1 Definitions 
10.1.1 Adverse Event  
An AE is defined in Title 21 Code of Federal Regulations (CFR) 312.32(a) as follows: 
• Any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related.  
An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign 
(eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of 
a drug, and does not imply any judgment about causality. An AE can arise with any use of the 
drug ( eg, off-label use, use in combination with another drug) and with any route of 
administration, formulation, or dose, including an overdose.  
10.1.2 Unexpected Adverse Events  
An unexpected AE is defined in 21 CFR 312.32(a) as follows: 
• An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the IB or is not listed at the specificity or severity that has been observed; or, if an IB is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended.  
10.1.3 Serious Adverse Event  
An SAE is defined in 21 CFR 312.32(a) as follows : 
An AE or suspected adverse reaction is considered “serious” if, in the view of either the Investigator or Sponsor , it results in any of the following outcomes:  
• Death  
• A life -threatening AE  
• Subject hospitalization or prolongation of existing hospitalization 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 62 of 83 
CONFIDENTIAL  • A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• A congenital anomaly/birth defect  
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the subject or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in subject hospitalization, or the development of drug dependency or drug abuse. 
An AE or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor , its occurrence places the subject or subject at immediate risk of death. It 
does not include an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused death.  
10.1.4 Definition of Dose -limiting Toxicities  
Dose -limiting toxicities are defined as events related to onvansertib that are considered an 
adverse reaction or suspected adverse reaction (per criteria in Section 10.1), during the first cycle 
of therapy and that fulfills at least one of the criteria listed below. Further information on the 
grading of AEs is presented in Section 10.2. 
Hematologic  
 Since marrow aplasia is an expected consequence of AML therapy, only persistent 
pancytopenia resistant to current standards of care that continues for ≥42 days and is not related to leukemic infiltration or another cause u nrelated to study therapy will be considered 
as a DLT . Bone marrow evaluation may be required. 
Non-Hematologic  
 Any Grade 3 abnormalities that persist >7 days without decreasing in severity despite standards of care, are clinically significant, or that are Grade 4 and symptomatic. The following will also be considered DLTs: o Aminotransferase abnormality ≥Grade 3 in the presence of elevated total bilirubin to >2× ULN (at least a Grade 2) with no other reason that can be found to explain the combination of incr eased A LT and total bilirubin , such as viral hepatitis A, B, or C; 
preexisting or acute liver disease; or another drug capable of causing the observed injury (Hy’s Law)  
o Nausea, vomiting or diarrhea Grade ≥3 persisting for >2 days without evidence of decreased severity (to at least Grade 2) despite maximal medical intervention  
o Serum amylase or lipase ≥Grade 3  accompanied by symptoms consistent with pancreatic 
injury 
o Neurologic toxicity ≥Grade 3 persisting for >2 days and not attributable to central nervous s ystem  leukemic infiltrate, external causes or concomitant medications  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 63 of 83 
CONFIDENTIAL  10.1.5 Determination of the Maximum Tolerated Dose  
The planned dose- escalation strategy for onvansertib in combination with either cytarabine or 
decitabine is presented in Section 8.1.1. 
In Phase 1b, the dose of onvansertib will be escalated in sequen tial dose cohorts, while the dose 
of either cytarabine or decitabine will be administered in the doses and regimens as per product 
insert. The onvansertib starting dose will be 12  mg/m2 (Dose Level 0), and escalated or reduced 
in dosing cohorts based on criteria outlined in Section 8.1.1. Dose modifications, delays and reductions for individual subjects will be performed as described in Sections  8.4.1.1.3, 8.4.1.1.4, 
and 8.4.1.1.5, respectively. DLTs  will be recorded for 28 days after initiation of therapy; 
however, if an I nvestigator elects to re -treat a subject prior to 28 days (allowed no sooner than on 
Day 22), the DLT evaluation period will end at the time of initiation of the second cycle therapy. 
Subjects may continue with additional cycles as long as the subject i s receiving clinical benefit 
and there are no safety or tolerability issues.  
Subjects who have not received at least 80% of the dose of study drug(s) during the first cycle or who are discontinued for any reason other than DLT will be replaced.  
The MTD o f onvansertib in combination with either low -dose cytarabine or decitabine in 
subjects with AML will be defined as the highest dose level achieved at which no more than 
1 out of 6 subjects experienced a DLT during the first cycle of therapy in Phase 1b.  
10.2 Severity of Adverse Events  
Each AE will be graded according to the NCI -CTCAE version 4.03 ( Appendix 19.1). In most 
cases AE terms will be listed in the CTCAE, with grading criteria specific to that term. If the AE is not specifically defined in the CTCAE, it is to be reported using the “Other, specify” term 
under the appropriate system organ class and graded according to the general CTCAE severity 
guidelines. 
10.3 Relationship of Adverse Events to the Study Drug 
The Investigator must attempt to determine if an AE is in some way related to the use of 
onvansertib, the study drug . All AE s must be attributed to study drugs unless there is a 
reasonably acceptable alternate cause for the AE s. This relationship should be described as 
follows: 
• Unrelated:  The event has no temporal relationship to study drug administration (too 
early or late or study drug not taken), or there is a reasonable causal relationship between 
the AE and another drug, concurrent disease, or circumstance.  
• Unlikely:  The event with a temporal relationship to drug administration which makes a 
causal relationship improbable, and in which other drugs, chemicals, or underlying disease provide plausible explanations.  
• Possibly : The event follows a reasonable temporal sequence from administration of the 
study drug and the event follows a known response pattern to the study drug BUT the event could have been produced by an intercurrent medical condition which, based on the 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 64 of 83 
CONFIDENTIAL  pathophysiology of the condition, and the pharmacology of the study drug, would be 
unlikely related to the use of the study drug or the event could be the effect of a concomitant medication.  
• Probably:  The event follows a reasonable temporal sequence from administration of the 
study drug and the event follows a known response pattern to the study drug AND the event cannot have been reasonably explained by an intercurrent medical condition or the event cannot be the effect of a concomitant medication.  
• Definitely:  The event follows a reasonable temporal sequence from administration of the 
study drug, the event follows a known response pattern to the study drug and based on the known pharmacology of the study drug, the event is clearly related to the effe ct of the 
study drug. 
10.4 Monitoring of Adverse Events 
AEs will be monitored continuously during the study starting immediately after the first dose of 
study drug is administered. Subjects will be instructed to report all AEs experienced during the study, and subjects will be assessed for the occurrence of AEs throughout the study. 
All AEs will be followed until resolution or stabilization of the event. This may require 
additional clinical assessments and laboratory tests.  
10.5 Reporting Procedures  
10.5.1 Routine Reporting  of Adverse Events  
AEs, whether or not associated with study drug administration, will be recorded on the AE form of the CRF and will be submitted to the Sponsor at regularly scheduled intervals. 
The information to be entered in the CRF will include: 
1. Time of onset of any new AE or the worsening of a previously observed AE. In most 
cases, date of onset will be adequate; however, for days when the subject is in the clinic and receives study drug(s), the time (based on a 24-hour clock) of onset should also be recorded  
2. Specific type of reaction in standard medical terminology  
3. Time of resolution of the event (or confirmation ongoing). In most cases, date of resolution will be adequate; however, for events that initiate and resolve on days where the subject is in the clinic and receives study drug(s), the time (based on a 24-hour clock) of resolution should also be recorded 
4. Severity/grade of AE. The severity should be rated according to NCI -CTCAE version 
4.03 ( Appendix 19.1) 
5. An assessment should be made of the relationship of the AE to the study drug according to the definitions outlined in Section 10.3. 
6. Description of action taken in treating the AE and/or change in study drug administration or dose 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 65 of 83 
CONFIDENTIAL  Follow-up assessments should be repeated to document return of any abnormalities to normal, or 
to document other outcome of the AE. 
10.5.2 Reporting of Serious Adverse Events, Including Death  
SAEs, including death due to any cause, which occur during this study or within 30 days 
following the last dose of the study drugs, whether or not related to the adm inistration of study 
drugs, must be reported to the Medical Monitor by telephone or email within 24 hours of 
learning of the event .  
SAE Forms will be provided by the Sponsor or Sponsor designated CRO. The study site should send the SAE Form to the Medical  Monitor as soon as possible so that the tracking procedure 
can begin immediately upon receipt of the information. Once the Medical Monitor is informed of 
an SAE with preliminary information obtained, the study site will be instructed to update the 
SAE For m with additional information, as per the following guidelines.  
If all information is not known at the time of the incident, an initial report should still be made. 
In the event there is a question as to whether the event is serious, the information should be 
forwarded to the Medical Monitor for review. The Investigator is responsible for following up on completion of the SAE Form. The Investigator will submit substantiating data in hard copy form, 
such as diagnostic test reports and progress notes, to the Medical Monitor. In the case of fatality, 
autopsy reports will be furnished to the Medical Monitor as soon as available. 
During the initial communication, the Medical Monitor will require the following information 
about the subject and the reported SAE: 
1. Subject identification including subject number, initials, and date of birth 
2. Date of first dose of study drugs and details of administration, including study drug 
names (including labeled strength and manufacturer), lot number, expiration date, and dose 
3. Date of last dose of study drugs ( ie, prior to onset of SAE) and details of administration, 
including study drug names (including labeled strength and manufacturer, lot number, expiration date, and dose) 
4. Medical diagnosis of the event in standard medical terminology (if a medical diagnosis cannot be determined, a description of each sign or symptom characterizing the event) 
5. Date of onset of the AE  
6. Date of resolution of the AE (or confirmation ongoing) 
7. Severity of the AE (see Section 10.2) 
8. Assessment of the attribution of the AE to the study drug  (see Section 10.3) 
9. Reason AE is considered serious (per definition in Section  10.1.3) 
10. Whether the AE  is expected (see Section 10.1) 
11. Action taken in treating the AE and/or change in study drug administration or dose (including concomitant medication s or therapies administered, whether hospita lization or 
prolongation of hospitalization was required, diagnostic procedures performed, and whether the subject was discontinued from the study) 
12. All concomitant medications (including doses, routes, regimens, and indications) 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 66 of 83 
CONFIDENTIAL  13. Pertinent clinical laboratory testing data  
14. Medical history  
The Investigator and the Medical Monitor will review each SAE report and evaluate the 
relationship of the adverse experience to study drugs and to underlying disease. Based on the 
Investigator’s and Medical Monitor’s assessment of the adverse experience, a decision will be 
made concerning the need for further action. The primary consideration governing further action is whether new findings affect the safety of subjects participating in the clinical study. If the 
discovery of a new adverse experience related to the study drug raises concern over the safety of 
continued administration of study drug, the Sponsor will take immediate steps to notify the regulatory authorities.  
Further action that may be required includes the following: 
1. Alteration of existing research by modification of the protocol 
2. Discontinuation or suspension of the study 
3. Alteration of the informed consent process by modification of the existing consent form and informing current study participants of new findings 
4. Modification of previously identified expected adverse experiences to include adverse 
experiences newly identified as study medication -related.  
Any SAE that is determined by the Sponsor to be reportable to FDA as an Investigational New 
Drug (IND) Safety Report [as defined in 21 CFR 312.32] will be reported to FDA by the 
Sponsor within the specified time frame. All IND Safety Reports will also be promptly provided 
to the Investigator for submission to his or her Institutional Review Board (IRB)/Independent Ethics Committee (IEC). Similarly, any SAE that is determined by the Sponsor to require 
expedited reporting to other regulatory authorities will be reported to the appropriate authorities 
by the Sponsor within the specified time frames, and will be provided to the Investigator for submission to his or her IRB/IEC. 
10.5.3 Other Events Requiring Immediate Reporting
 
10.5.3.1 Overdose  
An overdose is defined as a subject receiving a dose of investigational product in excess of that 
specified in the IB, unless otherwise specified in this protocol. Any overdose of a study subject 
with the investigational product, with or without associated AEs/SAEs, is required to be reported 
to the Medical Monitor within 24 hours of knowledge of the event. Overdose does not automatically make an AE serious, but if the consequences of the overdose are serious, for example death or hospitalization, the event is serious and must be reported as an SAE. 
10.5.3.2 Pregnancy 
Pregnancy in a female subject who has received investigational product is required to be reported 
within 24 hours of knowledge of the event. Should the Investigator become aware of a pregnancy of a female partner of a male participant, the pregnancy should be reported within 24 hours of 
knowledge of the event. The information should be captured on the Initial Pregnancy Report 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 67 of 83 
CONFIDENTIAL  Form (Please refer to the Site Operations Manual). After obtaining the subject’s consent (or 
subject and pregnant partner’s consent in the case of a male participant), monitoring of the 
pregnancy should continue until conclusion of the pregnancy whereby the Investigator will 
notify PRA of the outcome on the Pregnancy Outcome Report Form (Please refer to the Site Operations Manual).  
Subjects who become pregnant during the study period must not receive additional doses of investigational product but will not be withdrawn from the study.  
 
 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 68 of 83 
CONFIDENTIAL  11 SUBJECT DISCONTINUATION AND TRIAL DISCONTINUATION 
11.1 Subject Discontinuation 
A subject may choose to wit hdraw from this study at any time for any reason without penalty of 
jeopardizing their health care or loss of benefits to which the subject is otherwise entitled .  
Subjects will be discontinued from study drug (onvansertib) treatment if one or more of the 
following events occur: 
1. Clinically significant progressive disease  
2. Subject refusal to remain on study 
3. Pregnancy  
4. Non-compliance or inability to comply with protocol requirements by subject 
5. Development of unacceptable toxicity (regardless of study drug relationship) 
6. Determination by the Investigator that it is no longer safe for the subject to continue 
therapy.  
Subjects who have an ongoing AE at the time of discontinuation will continue to be followed until resolution of the event to Grade ≤1 or baseline, or until the event is considered irreversible.  
Subjects who are discontinued prior to completing the first tr eatment cycle for any reason other 
than toxicity, or who have not received at least 80% of the intended doses, will be replaced.  
11.2 Study Discontinuation 
Treatment may be continued longer at the discretion of the treating physician if there is no evidence of  disease progression and the subject is not experiencing unacceptable toxicity, and if 
both the subject and physician agree that further therapy is in the subject’s best interest.  
The Sponsor has the right to terminate this study, and the Investigator/Inve stigational Site has the 
right to close the site, at any time, although this should occur only after consultation between 
involved parties. The Investigator must notify the IRB/IEC in writing of a premature termination 
of a study or closure of Investigational Site, and must send a copy of the notification to the Sponsor.  
Events that may trigger premature termination of a study or closure of an Investigational Site 
include, but are not limited to, a new toxicity finding, a request to discontinue the study f rom a 
regulatory authority, non-compliance with the protocol, slow recruitment, or change in development plans for the study drug.  
 
 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 69 of 83 
CONFIDENTIAL  12 STATISTICAL METHODS  
12.1 Dosing Algorithm and Determination of Sample Size 
The planned sample size in the Phase 1b portion of the study is up to 84 subjects (42 in each 
arm), which is considered sufficient for the determination of safety and PK parameters for the study drug. 
This study is a dose- escalation study that initially utilizes a 3+3 design [ 19
] with a starting dose 
of onvansertib of 12 mg/m2 (Dose Level 0) administered Day 1 through Day 5 every 21 to 
28 days.  If an Investigator elects to re -treat a subject prior to 28 days (allowed no sooner than on 
Day 22), the DLT evaluation period will end at the time of initiation of the second cycle of 
therapy. The sample size is anticipated to be up to 84 subjects (42 per arm) in Phase 1b, 
depending on the dose level at which toxicity is observed. The 3+3 dose- escalation algorithm is 
as follows:  
1. If 0 out of 3 subjects experience DLT (as defined in Section 10.1.4) during the first cycle of therapy, the next cohort of 3 subjects will be treated at the next higher dose level.  
2. If 1 out of 3 subjects develop DLT during the first cycle of therapy ( ie, 28 days from start 
of therapy), an additional 3 subjects will be treated at the same dose level. If no additional DLT s occur during the first cycle of therapy for the additional 3 subjects treated (ie , 1 out 
of a total of 6 subjects develops DLT that initiates within the specified period), the dose 
escalat ion continues to next higher level for a cohort of 3 subjects.  
3. If at any time there are 2 or more subjects who  experience DLTs  in the 3 to 6 subjects at a 
given dose, the next cohort will receive a prior dose level or an intermediate dose level, agreed upon by the Sponsor, Medical Monitor, and Principal Investigator.  
With this 3+3 design, a dose with a ≥ 50% probability of causi ng a DLT has at most a 12.5% 
chance of satisfying the conditions for dose escalation after the first 3 subjects and a ≥50% chance of stopping at 3. With 6 subjects, there is at most a 17.2% chance of satisfying the 
conditions for dose escalation after 6 subjects. Phase 2 will proceed with a total of  32 subjects at 
the identified RP2D; however, if at any time during this phase more than 33% of subjects 
develop a DLT- level AE  (as per protocol), accrual will stop , and the RP2D will be reassessed in 
additional cohorts. 
Subjects who are discontinued prior to completing the first cycle for any reason other than 
toxicity or who have not received at least 80% of the intended doses, without experiencing DLT will be replaced.  
12.2 Statistical Analysis of Safety Data 
Data from all subjects who receive at least one dose of study drug (onvansertib) will be included in the safety analysis.  
Safety will be assessed primarily based on AEs. The severity of AEs will be graded as mild, moderate, severe, or life- threatening according  to NCI -CTCAE version 4.03 ( Appendix 19.1). 
AEs will be tabulated by system organ class and preferred term (per Medical Dictionary for 
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 70 of 83 
CONFIDENTIAL  Regulatory Activities [MedDRA]), and will be further categorized by onvansertib dose level, 
severity, and assigned relationship to study drug. The incidence for each AE will be provided as 
the total number of subjects who  experienced the AE, as well as the percentage of the population 
that this represents. If an AE is reported more than once during treatment for a given subject, the 
greatest severity and the worst -case attribution will be pre sented in the AE summary tables.  
AEs will also be listed for individual subjects, along with information regarding onset, duration, severity, relationship to study drug, and outcome. AEs that lead to withdrawal from the study will be listed and summarized.  A separate tabulation and listing of SAEs will also be generated.  
Secondary safety assessments, including physical examination, ECOG performance status, weight (for body surface area [BSA] calculation), vital signs, ECG measurements and clinical laborato ry testing (hematology, clinical chemistry, and urinalysis) will be listed and summarized. 
Descriptive statistics will be generated as appropriate ( ie, mean, median, range, and SD  for 
continuous data and frequency for categorical data). 
Inferential statistical analysis comparing the safety data among onvansertib dose levels or 
historical data is not planned. 
12.3 Statistical Analysis of Efficacy Data 
Data from all subjects who receive at least one dose of onvansertib in combination with either cytarabine or deci tabine will be included in the intention -to-treat (ITT) efficacy analysis. 
Subjects completing at least one cycle of treatment will be included in the per protocol efficacy analysis.  
The efficacy endpoints for this study include CR, CRi, PR, MLF, DOR, and OS. Further 
description of the efficacy measurements and response criteria for this study is presented in 
Section 9.3.1. 
Descriptive statistics will be generated as appropriate ( ie, mean, median, range, and SD ). Median 
survival statistics will be estimated using the Kaplan -Meier Time -to-Event. 
Inferential statistical analysis comparing efficacy data among onvansertib dose levels or 
historical data is not planned. 
The primary efficacy endpoint is the rate of CR + CRi in the Phase 2 portion of the study. Based 
on a population CR + CRi rate of 20% for either the combination of cytarabine plus onvansertib or decitabine plus onvansertib, with  32 evaluable patients in the primary analysis the 90% CI for 
the CR + CRi rate from the study will have an estimated precision of approximately 58% and width 0.23, and a 95% CI  would have an estimated precision of approximately 70% and width 
0.28. 
PK parameters to be determined will include C
max, Tmax, AUC 0-24, and t 1∕2, which will be 
estimated from plasma concentration data. The geometric mean and 95% CIs will be reported for 
all evaluable subjects.   
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 71 of 83 
CONFIDENTIAL  13 ACCESS TO SOURCE DOCUMENTS AND RETENTION OF 
RECORDS  
The Investigator will make the source documents for this study available for monitoring by the 
Sponsor or its representatives, or by regulatory authorities or health authority inspectors. 
Subject medical information obtained as a result of this study is c onsidered confidential and 
disclosure to third parties other than those noted below is prohibited. All reports and 
communications relating to subjects in this study will identify each subject only by their initials and number. Medical information resulting from a subject’s participation in this study may be 
given to the subject’s personal physician or to the appropriate medical personnel responsible for 
the subject’s welfare. Data generated as a result of this study are to be available for inspection on request by FDA or other government regulatory agency auditors, the Sponsor (or designee), and 
the IRB/IEC.  
The information developed in this clinical study will be used by the Sponsor in the clinical development of the study drug and therefore may be disclosed by the Sponsor as required for 
disclosure as a public company to other clinical Investigators, to other pharmaceutical 
companies, to the FDA, and to other government agencies.  
Any information, inventions, or discoveries (whether patentable or not), innovations, suggestions, ideas, and reports made or developed by the Investigator(s) as a result of conducting 
this study shall be promptly disclosed to the Sponsor and shall be the sole property of the Sponsor. The Investigator agrees, upon the Sponsor’s request and at the Sponsor's expense, to 
execute such documents and to take such other actions as the Sponsor deems necessary or 
appropriate to obtain patents in the Sponsor’s name covering any of the foregoing. 
The Investigator will retain all study documents  for at least 2 years after the last approval of a 
marketing application in an International Council for Harmonisation (ICH) region ( ie, US, 
Europe, or Japan), and until there are no pending or contemplated marketing applications in an 
ICH region. If no application is filed or if the application is not approved for such indication, the 
Investigator will retain all study documents for at least 2 years after the Investigation is 
discontinued and regulatory authorities have been notified.  
The Investigator will notify the Sponsor prior to destroying any study records. Should the 
Investigator wish to assign the study records to another party or move them to another location, 
the Sponsor must be notified in writing in advance. 
If the Investigator cannot guarantee this archiving requirement at the study site for any or all of 
the documents, special arrangements will be made between the Investigator and the Sponsor for 
storage. If source documents are required for continued care of the subject, appropriate copies for storage off- site will be made.  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 72 of 83 
CONFIDENTIAL  14 QUALITY CONTROL AND QUALITY ASSURANCE  
14.1 Data Collection 
All data required by the study protocol will be entered onto case report forms and must be 
verifiable against source documents. Case report forms will be completed for every subject who is enrolled in this study.  
Only authorized Investigational Site personnel will enter data on the case report forms. Any 
corrections to data entered into the case report form will be made in such a way that the original 
entry is not obscured. The date of the correction and the initials of the person making the 
correction will be documented.  
The case report forms will be kept up -to-date by the Investigator and the research staff at the 
Investigational Site. The Investigator will be responsible for reviewing all data and case report 
form entries and will sign and date each subject’s case report form, verifying that the information is true and correct.  
14.2 Study Monitoring  
The study will be monitored to evaluate the progress of the study, to veri fy the accuracy and 
completeness of the case report forms, to assure that all protocol requirements, applicable laws and/or regulations, and Investigator’s obligations are being fulfilled, and to resolve any inconsistencies in the study records.  
The Inves tigator will allow the study monitor to periodically review, at mutually convenient 
times during the study and after the study has been completed, all case report forms and office, 
hospital, and laboratory records supporting the participation of each subject in the study.  
The study monitor will compare the case report form data against source documentation in order 
to verify its accuracy and completeness. The Investigator and research staff will collaborate with the study monitor to resolve any identified data discrepancies in a timely manner.  
The study monitor will record any protocol deviations identified, including, but not limited to, subjects who  were enrolled even though they did not meet all eligibility criteria, subjects who 
took concomitant medications specifically prohibited by the protocol, and subjects who received the wrong study drug or incorrect dose. The Investigator and research staff will collaborate with the study monitor to identify the reason for each protocol deviation.  
The study moni tor will compare the Investigational Site study drug accountability record against 
the study drug inventory (unused and used) at the site. The Investigator and research staff will 
collaborate with the study monitor to resolve any identified discrepancies i n a timely manner.  
Each issue identified during study monitoring visits will be documented and reported to both the Sponsor and the Investigator.  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 73 of 83 
CONFIDENTIAL  14.3 Data Management 
After the case report forms have been reviewed by the study monitor and all identified 
discrepancies have been identified, the Investigator signed copy of the case report forms will be 
forwarded to Data Management. Queries generated by Data Management will be sent to the study site for resolution. The Investigator is responsible for the review and approval of all responses. 
All case report form data will be entered into a validated database and an electronic audit study 
of edits maintained. Laboratory data may be imported to the database electronically.  
The database will be authorized for lock once no data queries are outstanding, all study data are considered clean, and all defined procedures completed.  
14.4 Sponsor Audits  
At some point during the study, individuals from the Sponsor’s Quality Assurance group or their 
authorized representative may visit the Investigator’s site to conduct an audit of the study. The 
purpose of this visit will be to determine the Investigator’s adherence to the protocol, applicable regulations, and the Sponsor’s procedures, in addition to assessing t he accuracy of the study data. 
Prior to initiating this audit, the Investigator will be contacted by the Sponsor to arrange a convenient time for this visit. The Investigator and staff will cooperate with the auditors and allow access to all subject record s supporting the case report forms and other study- related 
documents. 
14.5 Inspection by Regulatory Authorities 
At some point during the study, a regulatory authority may visit the Investigator to conduct an inspection of the study. The Investigator and staff w ill cooperate with the inspectors and allow 
access to all source documents supporting the case report forms and other study- related 
documents. The Investigator will immediately notify the Sponsor when contacted by any regulatory authority for purposes of conducting an inspection. 
  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 74 of 83 
CONFIDENTIAL  15 ETHICS 
15.1 Declaration of Helsinki 
The stu dy will be conducted in accordance with the Declaration of Helsinki. [ 20]  
15.2 Good Clinical Practice and Regulatory Compliance 
This study will be conducted in accordance with the principles of GCP (current ICH guideline) 
and the requirements of all local regulatory authorities regarding the conduct of clinical studies 
and the protection of human subjects.  
15.3 Institutional Review Board/Independent Ethics Committee 
The p rotocol, ICF, IB, and any materials (such as advertisements, subject information sheets, or 
descriptions of the study used to obtain informed consent) for this study will be reviewed and approved by a duly constituted IRB/IEC. 
The Investigator will ensure that all aspects of the IRB/IEC review are conducted in accordance 
with current institutional, local, and national regulations. A letter documenting the IRB/IEC 
approval will be provided to the Sponsor prior to initiation of the study.  
Amendments to the protocol will be subject to the same requirements as the original protocol. A 
letter documenting the IRB/IEC approval will be provided to the Sponsor prior to 
implementation of the changes described in the protocol amendment. 
Revisions to the ICF will be reviewed and approved by the IRB/IEC prior to use in the study. 
The Investigator will inform the IRB/IEC of all reportable AEs. IND Safety Reports provided by 
the Sponsor to the Investigator will be promptly forwarded to the IRB/IEC by the Investigator. Updates to the IB provided by the Sponsor to the Investigator will be submitted to the IRB/IEC by the Investigator. 
The Investigator will submit all periodic reports and updates that the IRB/IEC may require. After 
completion or termination of the study, the Investigator will submit a final report to the IRB/IEC. 
The structure and content of the report will meet that described in Structure and Content of 
Clinical Study Reports E3 (ICH Harmonized Tripartite Guideline, dated 30 Nov  1995). 
15.4 Informed Consent  
No study-related procedures, including screening evaluations, will be performed until the subject has given written informed consent.  
The ICF will clearly describe the nature, scope, and potential risks and benefits of the study, in a 
language that the subject understands. The ICF will conform to all the requirements for informed 
consent according to ICH GCP and US FDA guidelines (21 CFR 50) and any additional elements required by the Investigator’s institution or local regulatory authorities. The 
Investigator will submit the ICF to the IRB/IEC for review, and will provide the Sponsor with a 
letter documenting the IRB/IEC approval prior to initiation of the study.  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 75 of 83 
CONFIDENTIAL  The IRB/IEC approved ICF will be given to each prospective participant. The subjects will be 
given ade quate time to discuss the study with the Investigator or site staff and to decide whether 
or not to participate. Each subject who agrees to participate in the study and who signs the ICF will be given a copy of the signed, dated, and witnessed document. The original signed ICF will be retained by the Investigator in the study files.  
The Investigator will also obtain authorization from the subject to use and/or disclose Protected Health Information (PHI) in compliance with Health Insurance Portability and Accountability Act (HIPAA) or equivalent. Written HIPAA authorization may be obtained as part of the informed consent process. 
If a protocol amendment substantially alters the study design or increases the potential risk to the 
subject, or the known risks of the study drug change over the course of the study, the ICF will be 
revised and submitted to the IRB/IEC for review and approval. The revised ICF must be used to 
obtain consent from subjects currently enrolled in the study if they are affected by the amen dment and to obtain consent from new subjects prior to enrollment. 
15.5 Emergency Departure from Protocol  
When an emergency occurs that requires a departure from the protocol for an individual, a departure will be only for that subject. The Investigator or other physician in attendance in such an emergency will, if circumstances and time permit, contact the Sponsor’s Medical Monitor 
immediately by telephone. Such contacts will be made as soon as possible to permit a decision as 
to whether or not the subject (for whom the departure from protocol was affected) is to continue in the study. The case report form and source documents will completely describe the departure 
from the protocol and state the reasons for such departure. In addition, the I RB/IEC will be 
notified in writing of such departure from protocol. 
  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 76 of 83 
CONFIDENTIAL  16 PUBLICATION POLICY 
All information and data obtained in the course of the study are the property of the Sponsor and 
are considered confidential. To avoid disclosures that could jeopardize proprietary rights, the institution and/or the Invest igator agree to certain restrictions on publications ( eg, abstracts, 
speeches, posters, manuscripts, and electronic communications), as detailed in the clinical study agreement.  
The publication or presentation of any study results shall comply with all applicable privacy laws, including, but not limited to, HIPAA or equivalent. 
  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 77 of 83 
CONFIDENTIAL  17 PROTOCOL AMENDMENTS AND MODIFICATIONS  
The Investigator will ensure that the study is conducted in accordan ce with the procedures and 
evaluations described in this protocol. The I nvestigator will not modify the protocol without first 
receiving Sponsor authorization to do so, except in those cases intended to reduce immediate risk 
of the subjects. The Sponsor is responsible for submitting protocol amendments to the 
appropriate gover ning regulatory authorities. The Investigator is responsible for submitting 
protocol amendments to the appropriate IRB/IEC. Approval by the IRB/IEC will be obtained 
before protocol modifications are implemented, except in those cases intended to reduce 
immediate risk to subjects.  
  
 TROV -052
 Clinical Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
 
Page 78 of 83 
CONFIDENTIAL  18 REFERENCES  
1. Döhner K,  Döhner H.  Molecular characterization of acute myeloid 
leukemia.  Haematologica.  2008;93:976–82. 
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer St atistics. CA Cancer J Clin. 2014;64(1):9-29. 
3. American Cancer Society Facts and Figures, 2014. https://www.cancer.org/research/cancer -
facts -statistics/all- cancer -facts -figures/cancer -facts -figures -2014.html  Accessed on 
29 April  2017. 
4. Estey EH. Acute myeloid leukemia: 2014 update on risk stratification and management. Am 
J Hematol.   2014 Nov ;89(11):1063-81. 
5. Wang ES. Treating acute my eloid leukemia in older adults. ASH Education Program Book. 
2014 Dec 5;2014(1):14-20. 
6. Stebhardt, K. Multifaceted polo- like kinases: drug targets and antitargets for cancer therapy. 
Nat Rev Drug Discov. 2010 Aug;9(8):643-60. 
7. Degenhardt Y, Lampkin T. Targeting polo -like kinase in cancer therapy. Clin Cancer Res . 
2010 Jan 15;16(2):384–9.  
8. Müller -Tidow C , Bug G , Lübbert M , et al. A randomized, open-label, pha se I/II trial to 
investigate the maximum tolerated dose of the polo -like kinase inhibitor BI 2536 in elderly 
subjects with refractory/relapsed acute myeloid leukaemia.  Br J Haematol.  2013 Oct;163(2): 
214-22. 
9. Schöffski P , Awada A , Dumez H , et al . A phase I, dose -escalation study of the novel Polo-
like kinase inhibitor volasertib (BI 6727) in subjects with advanced solid tumors. Eur J Cancer.  2012 Jan;48(2):179-86. 
10. Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trail of low- dose cytarabine 
with or without volasertib in  AML patients not suitable for induction therapy. Blood. 
2014;124(9):1426-33.  
11. Beria I, Bossi RT, Brasca MG, et al. NMS -P937, a 4,5-dihydro-1H-pyrazolo[4,3-
h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett . 2011 May;21:2969-74.  
12. Hartsink -Segers SA, Exalto C, Allen M, et al. Inhibiting Polo- like kinase 1 causes gro wth 
reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica. 2013 June;98:1539-46.  
13. Sero V, Tavanti E, Vella S, et al. Targeting polo -like kinase 1 by NMS-P937 in osteosarcoma 
cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs . 2014 Dec;32:1167-80.  
14. Valsasina V, Beria I, Alli C, et al. NMS -P937, an orally available, speciﬁc small -molecule 
polo- like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. 
Mol C ancer T her. 2012 April; 11(4):1006-16.  
15. Casolara A, Golay G, Albanese C, et al. The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56 acute monoblastic leukaemia. PLoS ONE . 2013 March;8(3):e58424.
  
16. Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc . 2016 June;5(6):e003264. 
TROV -052
Clinica
l Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
Page 79 of 83 
CONFIDENTIAL  17.Cheson BD, Bennett JM, K opecky KJ,  e t al. Revised recommendations of the International  
Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and  
reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol.
2003;21:4642-9.
18.NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. NCCN v1 2017  
AML-D . https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp
19.LeTourneau C, Lee J, Siu L. 2009 do se es calation methods in Phase I cancer clinical trials. J  
Natl Cancer Inst. 2009;101:708-20.
20.Declaration of Helsinki. https: //www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-
JAMA.pdf
21.Criteria
 Committee New York Heart Association. Nomenclature and criteria for diagnosis of 
diseases of the heart and great vessels: the Criteria Committee of the New York Heart 
Association . Ed. Martin Dolgin. Little, Brown, 1994.
22.Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55. 
TROV -052
Clinic
al Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
Page 80 of 83 
CONFIDENTIAL  19 APPENDICES: 
TROV -052
Clinical S
tudy Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
Page 81 of 83 
CONFIDENTIAL  19.1 Appendix 1: National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.03 
NCI-CTCAE version 4.03 will be used in this study for AE reporting. 
A copy of CTCAE version 4.03 can be downloaded from the Cancer Therapy Evaluation 
Program (CTEP). 
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf  
19.2 Appendix 2: New York Heart Association Functional Classification 
The New Yor k He
art Association ( NYHA) Functional Classification [ 21] provides a simple way 
of classifying the extent of heart failure. It places subjects in one of 4 categories based on how 
much they are limited during physical activity; the  limitations/symptoms are in regards to normal 
breathing and varying degrees in shortness of breath and or angina pain: 
Functional Capacity  Objective Assessment  
Class I Subject s wit h cardiac disease but without 
resulting limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. No objective evidence of 
cardiovascular disease  
Class II  Subjects w ith cardiac disease resulting in slight 
limitation of physical activity. They are comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or  anginal 
pain. Objective evidence of minimal cardiovascular disease  
Class III  Subjects wi th cardiac disease resulting in marked 
limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, dyspnea, or anginal pain. Objective evidence of moderately severe cardiovascular disease  
Class IV  Subjects with cardiac disease resulting in inability 
to carry on any physical activity without 
discomfort. Symptoms of heart failure or the 
anginal syndrome may be present even at rest. If Objectiv e evidence of severe 
cardiovascular disease  
TROV -052
Clinical S
tudy Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
Page 82 of 83 
CONFIDENTIAL  any physical activity is undertaken, discomfort 
increases.  
19.3 Appendix 3: ECOG Performance Status 
Grade  ECOG  
0 Fully active, able to carry on all pre- disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
Note: As previously published. [ 22] 
19.4 Appendix 4: Package Insert for Cytarabine and Dacogen™ (Decitabine) 
•Conventional cytarabine is no longer a branded product in the US. A copy of the product 
insert for generic cytarabine can be downloaded from the following link:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34803a0e-f54d-4147-8f9f-  
7d0e3a007756 
•A copy of the Package Insert for Dacogen (decitabine) can be downloaded from the  
following link:
https://www.otsuka-u s.com/media/static/DACOGEN-PI.pdf
Note that generic equivalents are availab
le. 
19.5 Appendix 5: Clinical Study Report PLKA-937-001 
A Phase 1 Dose Escalation Study of NMS-1286937 Administered to Adult Patients with 
Advanced/Metastatic Solid Tumors, dated 06 Apr  2016 
TROV -052
Clinic
al Study Protocol  
Amendment 2, Version 6.0  
Onvansertib (PCM -075) Date: 0 7 Aug 2019 
Page 83 of 83 
CONFIDENTIAL  19.6 Appendix 6: Torsades de Pointes Risk QT Interval Normogram 
Derive
d from: https://missouripoisoncenter.org/qt-nomogram- assessing -risk-torsades-de-pointes/ 
